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ABSTRACT 
 
Analytical chemistry plays a critical role in pharmaceutical research and 
development. A typical analysis includes separating and identifying active 
pharmaceutical ingredients and impurities, determining the quantity of 
counterions, residual solvents, moisture, heavy metals in drug substances and 
drug products, and analyzing drugs and their metabolites in biological fluids. 
Analytical method development and validation are arguably the most important 
procedures in analytical research and development, because the qualities of drug 
substance and drug product are controlled by using analytical methods. This 
dissertation focuses on the application of various analytical techniques towards 
pharmaceutical industry.  
 
An application of headspace gas chromatography/flame ionization 
detector (HSGC/FID) for determination of residual solvents in drug product has 
been studied in order to increase productivity of drug analysis in the 
pharmaceutical industry. The conditions of HS sampler and GC were optimized 
to make the HSGC method more sensitive, efficient and reproducible. The 
examples of real drug substance analyses demonstrate the broad application 
potential of this HSGC method in the determination of residual solvents in drug 
substances. 
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A simple, sensitive and robust liquid chromatography-tandem mass 
spectrometer (LC-MS/MS) method was developed and validated for highly 
polar aminoglycoside compounds gentamicin, kanamycin and apramycin. The 
effect of trichloroacetic acid (TCA) concentration on plasma protein 
precipitation and sample recovery was studied and an optimized concentration 
of 25-30% TCA were determined that gives the best sample recovery for 
aminoglycosides from rat plasma. 
 
Simple, sensitive and robust LC-MS/MS methods were developed and 
validated for the determination of lipopeptide polymyxins and glycopeptide 
vancomycin in rat plasma. The effect of TCA concentration on sample 
recoveries was studied. 
 
An efficient LC-MS/MS method was successfully developed and 
validated for determination of fifteen estrogens and metabolites in human serum. 
The sample derivatization procedures were optimized, and sample stability was 
assessed. The method was specific, accurate, precise, sensitive and linear within 
the calibration range. It had a comparable sensitivity to those from the typical 
published LC-MS/MS methods, while it had a much better LC separation 
 XVIII 
efficiency for separating all of the fifteen dansylated estrogens and metabolites 
with a significantly reduced elution time.    
 
Both CIEF and MALDI-MS are frequently used in protein analysis, but 
hyphenation of the two is not investigated proportionally. One of the major 
reasons is that the additives (such as carrier ampholytes and detergent) in CIEF 
severely suppress the MALDI-MS signal, which hamper the hyphenation of the 
two. A simple CIEF-MALDI MS interface is used and to explore its application 
in proteomics research. This study is to develop a simple means to alleviate the 
signal suppressing from CIEF additives, such as carrier ampholytes and 
detergent, on MALDI- MS signals.  
 
 1 
Chapter 1: INTRODUCTION 
 
1.1 Background 
Analytical chemistry plays a critical role in pharmaceutical research and 
development. A typical analysis includes separating and identifying active 
pharmaceutical ingredients and impurities, determining the quantity of 
counterions, residual solvents, moisture, heavy metals in drug substances and 
drug products, and analyzing drugs and their metabolites in biological fluids, 
e.g. plasma, urine and tissues [1-5]. Analytical method development and 
validation are arguably the most important procedures in analytical research and 
development, because the qualities of drug substance and drug product are 
controlled by using analytical methods. In order to develop successful analytical 
methods, three essential procedures should be established and verified, including 
sample preparation, analyte separation and detection [6].  
 
The purposes of sample preparation are: 1) isolating the analyte(s) from 
the sample matrix, e.g. excipients of formulations, proteins from biological 
fluids (blood, tissues, etc.), which may interfere or damage the analytical 
instruments or systems; 2) dissolving and diluting the samples or analyte(s) with 
proper solvents to proper concentrations in solutions [7-9]. The precision and 
 2 
accuracy of an analytical method depends largely on the reproducibility of the 
sample handling process, such as weighing, dissolution, and transferring steps 
[10,11]. Commonly used sample preparation procedures include: dissolution, 
sonication, solid phase extraction, liquid liquid extraction, and headspace (HS) 
sample extraction, etc [6].  
 
A successful separation may significantly reduce or eliminate the 
interferences from the sample matrix, other analytes and impurities, and enhance 
the accuracy, precision and sensitivity of the analytical method(s). A particular 
separation technique is usually selected based on the chemical and physical 
properties of the sample or analyte, such as melting point, boiling point, 
functional groups, molecular weight, pKa, polarity, volatility, solubility and 
stability [3,6,9]. Chromatography techniques are the most commonly used 
separation systems, instruments such as gas chromatography (GC), high 
performance liquid chromatography (HPLC), super critical fluid 
chromatography (SFC), capillary electrophoresis (CE), and thin layer 
chromatography (TLC). 
 
An appropriate detector(s) must be utilized to monitor or to detect the 
analyte with high accuracy, precision and sensitivity. Most of the commonly 
used chromatography instruments are connected with different types of 
 3 
detectors. For example, GC used to be connected with a flame ionization 
detector (FID), thermal conductivity detector (TCD), sulfur chemiluminescence 
detector (SCD), and electron-capture detector (ECD). HPLC and CE usually use 
ultraviolet absorbance detectors or fluorescence detectors.  
 
However, the pharmaceutical industry has increased its desire to adopt 
more stringent sample information requirements, higher sensitivity for 
impurities, and higher throughput for drug discovery and development [6]. The 
application of existing separation techniques to hyphenate with different types of 
detectors is the most popular way to meet these increasing industry standards 
[1,5,12]. One of the most exciting hyphenated technique was introduced by 
Hirschfeld in 1960’s by the combination of GC and mass spectrometry (MS) 
[13,14]. By combining different techniques, analytical chemists can maximize 
the advantages of all instruments to provide rapid, reliable and valuable data for 
pharmaceutical analysis.  Due to its high selectivity and sensitivity, MS is the 
most used of hyphenated techniques connecting with different separation 
systems, such as GC-MS, LC-MS, and CE-MS [12,15-19]. These hyphenated 
techniques are broadly adopted by the biopharmaceutical industry today.  
 
In addition, analytical method validation is a critical procedure to evaluate 
and verify the method reliability, ruggedness and robustness with a series of 
 4 
parameters, i.e. specificity, accuracy, precision, linearity and range, sensitivity, 
sample stability, etc.      
 
The objectives of this dissertation were to develop and validate a number 
of analytical methods using a series of modern analytical technologies, e.g. 
HSGC-FID, LC-MS/MS, CE-MS, etc, while following scientific and practical 
pharmaceutical industry guidelines.      
 
1.2 Headspace Gas Chromatography/Flame Ionization Detection  
Headspace, as a sample of pretreatment methods, is commonly used to 
collect the releasing volatile compounds from solid or liquid carrier and couple 
with GC separation to detect the organic impurities and contaminations in active 
pharmaceutical ingredients or environment samples.  
 
 
 
 
 
 
 
 
 5 
1.2.1 Description of Headspace (HS) 
 
Figure1.1. Description of Headspace Sampling. 
The headspace system is represented by the sealed vial (see in Figure 1.1). 
The distribution of the analyte between a gas and a liquid upon equilibrium is 
called equilibrium constant. When giving enough time and at a certain 
temperature, the analyte can reach its equilibrium and the relative amount of 
analyte in two phases is kept at a constant ratio.  
 
After the analyte has equilibrated in the HS vial, the GC injector uses a 
sample probe to puncture the HS vial septum. A carrier gas (Helium) flushes 
through the vial and pressurizes the gas phase into the GC injector loop. Once it 
enters into the loop, the gas phase is transferred to the GC separation system by 
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passing a heated transfer line to avoid any condensation during the transferring 
process [20].  
 
There are two types of the HS sampling techniques, static HS and 
dynamic HS sampling [21]. The static HS sampling is more easily automated 
than the dynamic HS sampling with purge and trap, but the dynamic HSGC has 
a higher sensitivity. This is because the static HS sampling requires longer 
equilibration time at the same equilibration temperature [22,23]. In order to 
increase the sensitivity of static HS sampling, the sample should be equilibrated 
at a higher temperature with a longer equilibration time. 
 
1.2.2 Description of Gas Chromatography/Flame Ionization Detection 
GC is based on the partitioning of the analyte between a stationary phase 
(liquid coating on the separation column) and a mobile phase (carrier gas) [24]. 
The carrier gas is usually helium. After the sample is injected into the GC 
injection port, the sample is vaporized and pushed by the carrier gas to flush 
through a stationary phase, at which the analyte interacts by volatility and 
solubility properties. The analytes with a higher affinity interaction for the 
stationary phase come out later than those having less interaction. The eluted 
analytes finally reach the detector.  
 
 7 
FID is the most commonly used GC detector. It is a typical destructive, 
mass related detector. According to the strength of the signal, the amount of 
organic compounds can be quantified by peak area. Its prominent advantage is 
almost as a universal detector for all organic compounds, especially for 
hydrocarbons. However, FID is not sensitive to water, carbon dioxide and other 
inorganic compounds [4,24].  
 
1.2.3 Coupling Headspace with Gas Chromatography/Flame Ionization 
Detection 
In the past, direct injection of volatile compounds into the GC column has 
been the most commonly used method [22]. It is widely used in pharmaceutical 
industry as a residual solvent analysis. However, in direct injection mode, all 
analytes in a sample solution are directly injected into the GC injector, but only 
less than 4 µL of sample may be injected into a capillary column under regular 
conditions, and those non-volatile analytes may not be able to be eluted out from 
a GC column, due to their high polarity, high boiling point or low volatility 
[25-28]. When the non-volatiles accumulate on a GC column, they may decrease 
the column efficiency, shorten the column lifetime, decompose themselves, 
generate artificial peaks and affect the following analysis [26,28].  
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In contrast, the major advantages of HS sampling over direct injection are 
that it may avoid the contamination from the non-volatile analytes to the GC 
column, and a much larger sample may be loaded to a HS sampler [20,25,27]. 
These may result in a low background from contamination and a method high 
sensitivity. Coupling HS with GC/FID, the sample throughput is highly 
increased and less maintenance is required compared with the direct injection.  
 
1.3 High Performance Liquid Chromatography/Mass Spectrometry 
During the development of chromatograohy techniques, HPLC has 
become the leading technique for the application of pharmaceutical separation 
analysis due to its high reliability and high throughput abilities. Meanwhile, MS 
can help to solve difficult pharmaceutical analysis by utilizing the various 
modes and ionization techniques. The combination of HPLC and MS is the most 
frequently used analytical technique in pharmaceutical industry for drug 
discovery and development.  
 
1.3.1 Description of High Performance Liquid Chromatography 
 
Nowadays, HPLC is the most popular separation method to analyze the 
vast majority of organic compounds, including polar or ionic molecules, which 
 9 
are not suitable for gas chromatography [6]. Another advantage of HPLC is that 
its stationary and mobile phase can be distinctly different combinations to meet 
the maximum needs of sample separation.  
 
HPLC, based on the different physical and chemical separation principles 
for the analyte between the stationary phase and mobile phase, is cataloged as: 
adsorption chromatography, partition chromatography, ion chromatography, size 
exclusion chromatography, and affinity chromatography [6,24]. The most 
commonly used partition chromatography, according to the relative polarity of 
the stationary phase and mobile phase, is classified as normal-phase partition 
chromatography and reversed-phase partition chromatography.  
 
When the polarity of the stationary phase is larger than that of the mobile 
phase, it is called the normal phase chromatography (NPC). Silica or alumina 
based particles are highly polar stationary phases. The less polar or non-polar 
solvents, such as hexane or ether, are used as the mobile phases. In NPC, the 
less polar component comes out earlier than the polar component because it is 
more soluble in the non-polar mobile phase. The hydrophilic interaction 
chromatographic (HILIC) column is the ideal choice for polar and hydrophilic 
compounds since its stationary phase is based on bare silica. The highly polar 
compound is retained on the HILIC column to achieve a good separation. 
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Analytes, such as very polar aminoglycoside compounds, amino acids, and 
peptide, usually have strong retention on HILIC column in NPC separation 
mode [29-31]. 
 
When the polarity of the stationary phase is less than that of the mobile 
phase, it is called reversed phase chromatography (RPC). In RPC, the stationary 
phase is non-polar, such as a long hydrocarbon chain on silica core, whereas the 
mobile phase is relatively polar, such as water, acetonitrile, and methanol. Most 
commonly, the hydrocarbon chain of the siloxane is a C8 chain (n-octyl) or a C18 
chain (n-octyldecyl) [24]. The most polar component elutes out from the column 
first since it has less interaction with the stationary phase and is more favorable 
to dissolve in the polar mobile phase than less polar components [32]. Increasing 
the polarity of the mobile phase will keep the polar component on the column 
longer and allow for an increased retention time. Nowadays, RP-HPLC is the 
most polar separation mode applied in pharmaceutical industry [33-35].  
 
1.3.2 Description of Electrospray ionization Mass Spectrometry (ESI MS) 
1.3.2.1 Fundamentals of Electrospray ionization 
ESI was first introduced by Yamashita and Fenn in 1984, and has become 
the most popular ionization technique for MS [36,37]. ESI is a soft ionization 
process which makes organic or bio-molecules generate multiple charged ions. 
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A diagram (Figure 1.2) illustrates the basic set-up and process in ESI ionization 
mechanism [38]. 
 
Figure 1.2. Scheme of Electrospray Ionization Process. 
 
Currently, the most popular ESI source is the turbo ion source, which has 
a top down orthogonal spray (shown in Figure 1.2) to improve instrument 
robustness and to avoid neutral droplets from entering into the orifice hole. 
Otherwise, the MS instrument will be clogged and eventually lose the analyte 
signals.  
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1.3.2.2 Quadruploe and triple quadrupole mass analyzer 
 
After fifty years of development, quadrupole and triple quadrupole MS 
are the most mature and most widely used small mass spectrometers. 
Quadrupole MS works as a mass filter and can achieve high resolution, 
high-mass range, fast analysis speed and low cost. Especially, triple quadrupole 
MS is the most powerful and popular mass analyzer to couple with HPLC to 
quantitate small molecules in pharmaceutical industry.  
 
There are four types of MS scan modes for triple quadrupole MS: 
precursor ion scan, product ion scan, neutral loss scan and multiple reaction 
monitoring (MRM) scan. Compared with the other three scan modes, MRM 
scan mode is the most frequently used scan for quantitation purpose due to its 
ion selectivity [39].  
 
MRM scan mode is illustrated as Figure 1.3 [39]. Sample mixtures 
containing P, M, and N are introduced into triple quadrupole MS. After ESI 
process, P, M, and N lose electrons and become charged ions. When these ion 
species pass through Q1 mass filter, only the selected M+ precursor ion can enter 
into Q2 collision cell to collide with collision cell gas (CAD) gas and form 
fragmentations. In order to have a better selectivity for the monitored 
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compound, only the selected m/z fragmentations can pass through Q3 
quadrupole mass filter, and the other product ions lose in Q3 quadrupole. In 
MRM scan mode, only the selected precursor-product ion pair can record by the 
detector, which maximizes the ion selectivity and minimizes the background 
noise from the sample matrix [39]. 
 
1.3.3 Coupling High Performance Liquid Chromatography with Mass 
Spectrometry 
Nowadays, a lot of commercially available HPLC can couple with MS, 
which is contributed by the advanced interface design. For example, as shown in 
Figure 1.2, two symmetric turbo heaters and dried gas1 and gas2 can assist the 
solvent evaporation process. And the orthogonal spray mode also allows HPLC 
to carry up to 1 mL/min flow rate since most of the solvents go directly into the 
waste and only the margin area analyte is introduced into MS analyzer. Since the 
ionization process requires good solvent evaporation, the usage of non-volatile 
buffers or solvents will lead to damage the MS instrument and be prohibited to 
use. Only volatile buffers (containing formic acid, acetic acid, ammonia, formic 
acetate, and ammonia acetate, et al.) and mobile phase (water, methanol, and 
acetonitrile, et al.) are allowed to be introduced into HPLC followed by MS 
analyzer.  
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1.4 Capillary Electrophoresis/Mass Spectrometry 
At the present time, proteomics is the most promising area in 
academics and industry because it can offer a rich amount of information for 
cancer related biomarker studies. CE gives high separation efficiency for 
proteins and makes it possible for isolating low abundance biomarker 
proteins. MS utilizes the extremely sensitive detector and plenty of 
information to identify and quantify biomarker proteins. The coupling of CE 
and MS opens a new field for drug discovery and development based on 
biomarker studies. 
 
1.4.1 Description of Capillary Electrophoresis 
Capillary electrophoresis, including electrophoresis, chromatography 
and others, utilizes the capillary as the separation channel, the high-voltage 
electric field as the driving force, and a variety of sample physical properties 
as the separation mechanism (such as charge, size, isoelectric point, polarity) 
[24,40]. It is a micro-liquid separation technique, which only needs a few 
microliters of the total sample and buffer consumption. CE is another 
significant progress for analytical chemistry after HPLC separation 
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technique. It makes up the analytical subject from the microliter level to the 
nanoliter or sub-nanoliter level, and offers a great opportunity to proteomics 
[41]. 
 
There are several separation modes for capillary electrophoresis, such 
as capillary zone electrophresis (CZE), capillary gel electrophoresis (CGE), 
and capillary isoelectric focusing (CIEF) [40]. In this dissertation, CIEF is 
the main focus area for protein separation and will be discussed in detail as 
follows. 
 
1.4.2 Fundamentals of Capillary Isoelectric Focusing 
1.4.2.1 Description of Carrier Ampholytes 
Among different CE techniques, CIEF is the most attractive separation 
technique for proteomics research, due to its high resolution and 
auto-biological sample focusing ability, especially when used for 
ampholytes, such as proteins and peptides [40,42]. In CIEF separation, 
carrier ampholytes are the key componenets for building up the pH gradient 
in capillary. In 1961, Svensson first introduced the term of carrier ampholyte, 
which claims that in an electric field a continuous and stable pH gradient is 
established by the mixtures of ampholyte compounds [43]. Those 
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compounds are the synthetic heterogeneous mixtures of isomers of 
polyamino polycarboxlic acids [42,44]. They have some unique physical and 
chemical properties, such as low molecular weight (1,000 – 15,000 Da), high 
buffering capability, good solubility, good electric conductivity, and absence 
of biological effects, to ensure them as the carriers to separate different 
proteins or peptides [42]. 
 
1.4.2.2 Capillary Isoelectric Focusing Process 
In CIEF (see Figure 1.4), a mixture of carrier ampholytes and proteins 
is introduced into a capillary by pressure, and a DC voltage is applied at the 
same time. A pH gradient is generated and the analyte is separated based on 
the different pI, spontaneously concentrating themselves in their pI ranges, 
which are specific for each ampholyte analyte with net zero charge. When 
the proteins are focused in the capillary, the protein zones are mobilized 
toward a detector by hydrodynamic mobilization. 
 18 
 
Figure 1.4 Schematic diagram of apparatus for CIEF. 
 
1.4.3 Description of Matrix-assisted Laser Desorption/Ionization Time of 
Flight Mass Spectrometry (MALDI-TOF-MS) 
1.4.3.1 Fundamentals of Matrix-assisted Laser Desorption/Ionization 
Matrix-assisted laser desorption ionization time of flight mass 
spectrometry (MALDI-TOF-MS) is a recently developed type of soft 
ionization mass spectrometry. The instrument consists of two parts: 
matrix-assisted laser desorption ionization ion source (MALDI) and time of 
flight mass analyzer (TOF) [24]. The principle of MALDI is to use the 
sample and matrix mixture to form a thin film of crystals on the MALDI 
target plate. The plate is loaded into the high vacuum ion source. When the 
laser beam shots onto the sample spot, the crystal absorbs the laser energy 
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and transfers this energy to the biological molecules, and the ionization is 
induced, which is the process of proton transfer to or from the biological 
molecules. Finally, the biomolecules like proteins or peptides are charged 
and form the precursor ions [45,46]. High voltage is applied to the sample 
plate, accelerating ions into the flight tube and detected by mass analyzer.  
 
1.4.4 Coupling Capillary Isoelectric Focusing with Matrix-assisted Laser 
Desorption/Ionization Time of Flight Mass Spectrometry 
The development of interfaces between CE and MS has been reviewed 
and proven as much more difficult than the interface of LC and MS [47-50]. 
Here, only interfaces between CIEF and MS are briefly summarized [51,52]. 
After the process of protein focusing in CIEF separation, the key thing is the 
sample individual collection and transportation to MS detection instruments. 
The biggest problem is the transferring step can distort the pH gradient in the 
capillary, which leads to a broadened focus zone, loss of resolution between 
two bands, expended elution time, and poor reproducibility [42,51]. In order 
to decrease the influence of band broadening and coupled with MS, 
researchers have developed several different methods to individually collect 
or on-line transfer fractions [53-57]. The mobilization can utilize either by 
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electrophoretic flow with sheath liquid assistant or by hydrodynamic flow 
with the elevation of the inlet capillary end. 
 
The on-line CE-electrospray ionization (ESI) MS hyphenated method 
is more suitable for automation. Tang et al. first accomplished the coupling 
of ESI-MS with CE [19,58]. Different interfaces have been applied to 
improve the CE-MS coupling, such as coaxial liquid-sheath flow, 
microdialysis membrane device, and sheathless nanoflow interfaces, to 
minimize the influence from the additives in CE separations [49,50,54]. 
Foret et al. coupled CIEF with MALDI-TOF MS because MALDI-TOF MS 
can tolerate relatively high amounts of these additives [59]. Furthermore, 
off-line coupling of CIEF to MALDI MS can provide the high resolution 
from CIEF separation and the high mass accuracy and structural information 
from MALDI. 
 
CIEF can be coupled with MALDI-TOF MS in several different ways: 
fraction collection, directly depositing the effluent onto MALDI plate, or 
separation in microchip channels and then using microchip as a target plate 
[60-63]. Among different methods available, direct spotting is the simplest 
approach. Wang et al. successfully used a porous joint made of a cellulose 
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acetate membrane for off-line CE-MALDI experiment for neuropeptide 
analysis of complex tissue samples [64].  
 
1.5 Dissertation Synopsis 
This dissertation focuses on the application of various analytical 
techniques towards pharmaceutical and bioanalytical problems. Chapter 2 
will presents an application of HS-GC/FID towards a problem of interest to 
the pharmaceutical industry. The goal of this study is to develop and validate 
an efficient and sensitive generic HS-GC method for determination of 
residual solvents in drug substance in order to increase productivity of drug 
analysis in the pharmaceutical industry [65].  
 
In Chapter 3, a study of highly polar aminoglycoside compounds, such 
gentamicin, kanamycin, and apramycin, will be discussed in biological 
matrix by using LC-MS/MS. The goals of this study are not only introduce a 
method for analysis of aminoglycoside compounds, but also compare the 
behaviors of amimoglycoside compounds on a HILIC column and a 
hydrophobic column. The effect of trichloroacetic acid concentration on 
plasma protein precipitation and sample recovery efficiency will be 
discussed in this chapter [66]. 
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Chapter 4 will present simple, sensitive and robust LC-MS/MS 
methods for the determination of peptide drugs, such as lipopeptide 
polymyxins and glycopeptide vancomycin in biological matrix. The purpose 
of this study is to develop and validate a general bioanalytical method based 
on the same principle for the antibacterial peptide compounds [67].  
 
In Chapter 5, a study of female hormones and their metabolites in 
human serum will be presented by the application of LC-MS/MS. Many 
concerns of the existing methods will also be studied in Chapter 5, such as 
sample derivatization, method specificity, sensitiviy, separation efficiency 
and long running time. Compared to the vast existing analytical methods in 
the literature, the LC-MS/MS used in this dissertation can be precessed 
quickly and having the similar or better sensitivity. This procedure will 
largely accelerate the sample throughput efficiency in the diagnosis of 
hormone related cancers.  
 
Chapter 6 will describe a simple CIEF-MALDI MS interface in order 
to explore its application in proteomics research. The main goal of this study 
is to develop a simple means to alleviate the signal suppressing from CIEF 
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additives, such as carrier ampholytes and detergent, on MALDI MS signals 
[68].  
 
Chapter 7 will give an overall conclusion and discuss the future 
directions of the research presented in this dissertation.  
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Chapter 2: Headspace GC/FID for the analysis of residual solvent in 
drug substance. 
 
2.1 Introduction 
Residual solvents are critical impurities in drug substances, drug 
products and excipients, because they may cause toxicity and safety issues, 
and affect physicochemical properties of drug substances and drug products. 
In order to control residual solvent contents in drug substances, products and 
excipients, ICH Q3C guideline provides specific criteria for class 1 solvents 
(5)--known or suspected human carcinogens or environmental hazards, class 
2 solvents (26)--suspected of other significant but reversible toxicities, and 
class 3 (28) solvents--low toxic potential to man [69]. Therefore, 
determination of residual solvents becomes a necessary procedure for quality 
control of drug substances and drug products to meet regulatory expectations 
and ensure patient safety.    
 
Developing and validating an efficient and sensitive generic 
analytical method for the determination of residual solvents may 
significantly increase productivity of an analytical laboratory in the 
pharmaceutical industry. Determination of residual solvents using GC with a 
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flame ionization detector (FID) is the most common technique in the 
pharmaceutical industry, because of its high separation efficiency and 
sensitivity for volatile organic compounds. GC analysis may be performed 
by either direct injection or HS sampling [22]. The advantage of the direct 
injection mode is that all analytes in a sample solution are directly injected 
into the GC, leading to a lower sample load or sample requirement and a 
simpler analytical procedure. But, the high boiling/melting point or polar 
components of the sample may not be eluted through a GC column, and they 
may contaminate the GC injection port and/or column. In contrast, HS 
sampling can prevent this from occurring, but it limits the analysis to those 
solvents being evaporated from the HS only, and it requires a larger sample 
load. In addition, the analysis time can be longer due to sampler equilibration 
prior to injection on column.        
 
There are two types of HS sampling techniques, static HS and 
dynamic HS sampling. The static HS sampling is more easily automated. 
Dynamic HS sampling with purge and trap is less suitable for automation but 
has a higher sensitivity [22,70]. Currently, static HSGC with FID is more 
popular for analyzing residual solvents in drug substances [25,27,71-73] and 
drug products [21,26,28] in the industry. Static HS sampling is based on 
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thermostatic partitioning of volatile compounds in a sealed vial between the 
sample diluent and the gas phase. Sample diluent is a critical factor affecting 
HSGC method sample load, sensitivity, HS equilibration temperature and 
time. A good sample diluent for analyzing residual solvents in drug 
substances or drug products should have a high capability for dissolving a 
large amount of samples, a high boiling point and a good stability. There are 
a number of commonly used sample diluents for HSGC analyses, such as 
water, DMSO, N,N-dimethyformamide (DMF), N,N-dimethylacetamide 
(DMA), benzyl alcohol (BA), 1,3-dimethyl-2-imidazolidinone (DMI), and 
mixtures of water-DMF or water-DMSO [74]. 
 
Water is a good diluent for water soluble samples and analytes, 
because it is clean, stable and inexpensive. However, many organic synthetic 
drug substances and drug products have low water solubilities, which would 
limit the sample load. Meanwhile, using water as a diluent may also lead to a 
lower method precision than organic solvent, like DMF [25]. When a 
mixture of water-DMF or water-DMSO is used as a sample diluent, it may 
increase the solubility of many drug substances or drug products, and 
decrease the partition coefficient of the analytes, resulting in better transfer 
of analytes from the diluents to the gas phase, and improved method 
 27 
sensitivity [21,27,28]. If the sample diluent uses these aqueous mixtures, two 
other important factors, HS equilibration temperature and time, must be 
taken into consideration for obtaining HS equilibration efficiency. It is 
required that the HS equilibration temperature should be lower than the 
boiling point of the sample diluent. Otherwise, if the sample was equilibrated 
at or above the boiling point of the sample diluent, e.g. water at 100 °C, a 
large amount of sample diluent may be vaporized (at 100 °C), resulting in a 
dangerously high sample vial pressure, and a flood of the sample diluent and 
analytes to the GC system. This means that if water or water-organic mixture 
is chosen as the sample diluent, the HS equilibration temperature must be 
lower than 100 °C, i.e. 75-80 °C [25,27,28,74]. However, more than half of 
the organic solvents listed in ICH guideline Q3C may not be fully vaporized 
below 100 °C, because their boiling points are higher than 80 °C. In order to 
increase method sensitivity, equilibration at a low HS oven temperature 
requires a longer equilibration time, e.g. 30 to 90 minutes [25,27,28,74], to 
obtain a good phase distribution of the volatile compounds between the gas 
phase and the sample diluent.        
 
In contrast, those organic solvents, e.g. DMSO (b.p. 189 °C), DMF 
(b.p. 153 °C), DMA (b.p. 166 °C), BA (b.p. 204 °C), and DMI (b.p. 105 °C), 
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may provide better solubilization of sample, and they also have higher 
boiling points than water. When they are used as the sample diluents for 
HSGC, higher method sensitivity due to better solvent recoveries and 
improved method precision were observed [70,74,75]. However, DMF, 
DMA and BA are not very stable at high temperature and are susceptible to 
degradation when exposed to ultrasonic wave energy during sample 
preparation. The degradants from high HS equilibration temperature or 
sonication process during sample preparation may interfere with the analyses 
of the residual solvents [74]. Since DMSO is more stable at high temperature 
than the other solvents, e.g. DMF and BA, and has a higher capacity of 
dissolving drug substances and drug products, as well as a higher boiling 
point than water, it is a better sample diluent for HSGC analyses.  
 
A number of parameters may affect GC method sensitivity and 
separation efficiency, such as sample injection split ratio, GC carrier gas 
linear velocity or flow rate and oven temperature program (isocratic or 
gradient). The typical GC parameters for a generic separation of residual 
solvents in previous publications are: split ratio 1:5-20; carrier gas linear 
velocity 20-36 cm/s; oven temperature at 40 °C isocratic, or with gradient 
programming from 40 °C to 90-160 °C at 5-10 °C/min [25,27,70-72,74,75]. 
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These parameters may be optimized for separation efficiency and detection 
sensitivity for determining specific ICH Q3C solvents. 
 
The objective of this study was to develop and validate a generic 
HPGC method which has a shorter sample equilibration time, a better 
separation for most of the interested solvents, a higher sensitivity and a 
broader concentration range. We selected 4 mL of DMSO as the sample 
diluent for 200 mg of drug substance in order to develop a generic HSGC 
method with efficient HS equilibration, GC separation and high detection 
sensitivity. We assessed a number of HSGC parameters, as listed in Table 
2.1. Since class 1 solvents (5) are highly carcinogenic or toxic, they are 
generally avoided in pharmaceutical manufacturing. Only ICH class 2 (26) 
and class 3 (28) solvents were evaluated during this method development. 
The method validation was performed to demonstrate the method specificity, 
accuracy, precision, linearity and sensitivity. There are a number of 
calibration methods for the determination of residual solvents in drug 
substances by HSGC, such as calibrations using external standard, internal 
standard and standard addition, but there are no significant differences 
among these approaches with respect to accuracy and precision [27,76]. 
Therefore, we used an external standard approach in this method, and 
 30 
evaluated the drug substance matrix impacts on residual solvents recoveries 
using four synthetic small molecule drug substances during method 
validation. 
 
2.2. Experimental 
2.2.1 Reagents and chemicals 
The drug substances were synthesized by Astrazeneca Pharmaceuticals 
LP (Wilmington, USA). Solvents used were of ≥ 98% purity, and purchased 
from the following sources: acetone, acetonitrile, n-heptane and toluene from 
Fisher Scientific (Fairlawn, NJ, USA); formic acid and acetic acid from 
Acros Organics (Geel, Germany); ethyl ether from J. T. Baker (Phillipsburg, 
NJ, USA). The remaining organic solvents were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).  
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2.2.2 Instrumentation 
An Agilent 6890A GC equipped with an FID and a 7694 HS sampler 
was used for the experiments. The HSGC system was controlled using 
Agilent Chem32 software, and data acquisition and processing were 
accomplished using Thermo Atlas software. The GC column was an Agilent 
DB-624 (6% cyanopropylphenyl/94% dimtheyl polysiloxane) fused silica 
capillary column, 30 m long, 0.32 mm I.D., 1.8 μm film thickness (Part No. 
123-1334, serial No. US1613334H). The HSGC parameters assessed during 
the method development and validation are listed in Table 2.1.  
 
2.2.3 Standard solutions 
The ICH Q3C class 2 and 3 solvents (54) were prepared at about 1000 
ppm individually in DMSO, and injected to the HSGC system. Since ten of 
these 54 solvents were not suitable for the current method due to their high 
boiling points or high polarities, only 44 of these solvents were used for the 
method validation experiments. In order to obtain good separations and 
proper signal strength, these 44 solvents were separated as three groups, I 
(26), II (9) and III (9), respectively. The concentrations of these solvents 
were prepared in ranges of 0.2-15,000 ppm (from the quantitation limit to 
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full GC chromatogram scale) by sequential diluting high concentration stock 
mixture solutions with DMSO to 10 concentration levels, because the 
sensitivity of these solvents to FID varies significantly. Two identical 
samples were prepared for the accuracy test for each group mixture at 20-900 
ppm levels.  All the solvent concentrations were calculated based on 200 
mg drug substance being dissolved in 4 mL of DMSO. For the HSGC 
analysis, 4 mL (sample load) of the standard solutions was pipetted into an 
Agilent 20 mL headspace sample vial and immediately sealed with a 
Teflon-lined septum and an aluminum crimp cap (Agilent, Wilmington, DE, 
USA).  
 
2.2.4 Drug Substance Sample Solution 
The four drug substances were dissolved individually (200 mg each) in 
4 mL of blank DMSO or in the three group mixtures at both working 
concentration (20-900 ppm) and low concentration (2-90 ppm) levels. For 
example, 200 mg for one drug substance was weighed in seven HS sample 
vials, 4 mL of blank DMSO was added into the first vial; then either 4 mL of 
groups I, II or III solvent mixtures at working concentration levels (20-900 
ppm) was added; or 4 mL of groups I, II or III solvent mixtures at low 
concentration levels (2-90 ppm) was added. All the solvent concentrations 
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were calculated based on 200 mg drug substance being dissolved in 4 mL of 
DMSO. The sample solutions were vortexed using a Thermolyne mixer 
(Dubuque, IA, USA), and sonicated for 5 minutes using a Bransonic 3200 
(Danbuty, CT, USA) to dissolve all samples completely. The samples for 
each drug substance were prepared in duplicate.  
 
2.2.5 Procedure 
During the HSGC method development, in order to select the most 
appropriate system parameters to obtain the best separation, sensitivity and 
time efficiency, 54 class 2 and class 3 solvents, and typical samples of the 3 
groups of solvent mixtures were injected under a variety of conditions, e.g. at 
different HS oven temperatures (125-150 C), equilibration time (8-15 
minutes), GC gradients (35-280 C, ramping speed 3-10 and 10-40 C/min), 
carrier flow rate (28-40 cm/sec), sample split ratio (1:1-5:1), etc. The final 
HSGC conditions used for method validation were obtained based on 
optimized HS and GC parameters. 
 
The HSGC system was equilibrated under the experimental 
conditions by injecting 3 blank DMSO samples every day before sample 
sequence injections. Each of the ICH Q3C class 2 and 3 solvents (54) was 
 35 
injected once separately to determine method specificity and signal response 
sensitivity. Since 10 of these 54 solvents are unsuitable for the current 
method due to their high boiling points or polarities, only 44 of these 
solvents were used for the method validation experiments, and they are 
separated as three groups according to their retention behavior and 
detectability by FID.  
 
The method validation experiments of these 44 solvents were 
performed by injecting the 3 groups of solvents sequentially from low to 
high concentrations to determine the method specificity, sensitivity, linearity, 
accuracy and precision. Each of the 3 groups of solvent mixtures at working 
concentrations (20-900 ppm for accuracy and precision testing) and at low 
concentrations (2-90 ppm for sensitivity testing) were injected six times on 
the first day of experiment, and one time in each of the following five days. 
The samples of four drug substances in blank DMSO and in three spiked 
groups of solvent mixtures at 2-90 ppm and 20-900 ppm levels were injected 
once to evaluate the method feasibility to drug substance and the impact of 
drug substance on the recoveries of those solvents. 
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2.3 Results and discussion 
2.3.1 Optimization of HS conditions 
The HS sampler has a number of parameters affecting the method 
sensitivity, precision, and efficiency, including: temperature (oven, transfer 
line, and loop), time (vial equilibration and pressurization, loop fill, and 
injection), pressure (vial and carrier gas) and phase ratio (vial size and 
sample volume). Selecting a proper sample diluent for HSGC analysis is 
very critical for method sensitivity, precision and sample equilibration 
temperature and time, and it will affect the final optimized HS conditions. 
When we evaluated HS equilibration temperature at 125 C, 140 C and 150 
C with equilibration times of 8, 10 and 15 minutes, many solvents with 
boiling point higher than 125 C could not evaporate efficiently at 125 C 
within 15 minutes, while a significant amount of DMSO evaporated at 150 
C even in 8 minutes, overloading the GC column, and interfering with the 
method separation efficiency. When the equilibration time at 140 C was 
extended from 10 to 15 minutes, the recoveries of the 44 class 2 and class 3 
solvents remained constant. Therefore, we determined that equilibrating at an 
oven temperature of 140 C for 10 minutes was optimal. It was observed that 
when the temperatures of the injection loop and the transfer line were 10 C 
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higher than the HS oven temperature of 140 C or kept the same as that of 
the oven temperature, there was no significant change in solvent recoveries. 
However, when the HS sampler was equilibrated at 140 C, those ICH Q3C 
solvents with a boiling point higher than 150 C, as listed in Table 2.2, could 
not be analyzed by this HSGC method. 
 
Table 2.2 ICH class 2 and class 3 solvents unsuitable for this HSGC 
method. Reprinted from [65] with permission. 
 
 
 
2.3.2 Optimization of GC separation  
The choice of GC column is crucial for establishing an efficient and 
robust HSGC method. The Agilent DB-624 column (30 m X 0.32 mm I.D., 
1.8 m) is a commonly used column for residual solvents determination, 
because of its medium polarity. Most of the ICH Q3C class 2 and 3 solvents 
can be resolved by the Agilent DB-624 column except formic acid and acetic 
acid, due to their high polarities. To obtain efficient separation and sample 
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sensitivity, a number of GC parameters were evaluated when developing this 
method, such as the GC oven temperature gradient, carrier gas flow rate and 
sample split ratio: initial temperature 35 C at different holding time (0, 1, 3, 
and 5 minutes), temperature ramping rate (2, 3, 4, 5, 8, 10 C/min), carrier 
flow rate (1.5, 1.8, and 2.0 mL/min) and split ratio (splitless or 1 to1-5 ratio). 
Our data indicated that the GC parameters listed in section 2.2.2 were the 
most efficient combination for separation and sensitivity of this method. 
Under these optimized conditions, 44 of class 2 and class 3 solvents were 
analyzed by this method. The separation efficiency of this method is better 
than previously reported methods, because more class 2 and class 3 solvents 
can be resolved by this method. Another advantage of our generic HSGC 
method is its capability to separate most of the frequently used solvents in a 
considerably shorter time (total running time is 40 minutes, including 10 
minutes for HS vial equilibration and 30 minutes for GC separation) 
compared to previously reported methods [25,27].  
 
2.3.3 Method validation 
2.3.3.1 Specificity 
The typical HSGC chromatograms of 44 ICH Q3C class 2 and 3 
solvent standards are shown in Figure 2.1. As indicated in the retentions of 
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these solvents in Table 2.3, most of these solvents (33) are well separated 
from each other and DMSO, but some of the solvents in Group II and Group 
III are incompletely resolved with those in Group I, such as Ethyl formate 
(III) and 2-Propanol (I). However, there are rare cases when a drug substance 
contains more than five residual solvents at or around meaningful detection 
limits. For example, each of the four drug substances evaluated in this study 
contain a mixture of two to four residual solvents at or above the quantitation 
limits of this HSGC method, as shown in Figure 2.2. That means this HSGC 
method is a suitable approach in many pharmaceutical applications for 
screening and determining the 44 ICH Q3C solvents.  
 
2.3.3.2 Linearity 
The method linearity was investigated using ten concentration levels 
ranging from 0.2 to 15 000 ppm, and the linearity of each solvent was 
assessed using linear regression. Since the sensitivity of each of the 44 
solvents to FID varied significantly, the concentration ranges of each organic 
solvent were adjusted during the sample preparation procedures to obtain a 
relatively reasonable peak height for each organic solvent and to cover 
appropriate linear ranges. As shown in Table 2.3, the regression coefficients 
(r2) of these 44 solvents are within the range of 0.9990-1.0000. The 
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intercepts of these regression lines are less than 2% of the high calibration 
concentrations (20-900 ppm) for all 44 solvents. This means that the 44 
solvents have linear responses within the calibration ranges studied, which 
are broader than ICH guideline detection range of 50-5 000 ppm.  
 
2.3.3.3 Accuracy 
Accuracy of this method was determined by analyzing duplicate 
sample preparations of the three groups of the ICH Q3C solvents at working 
concentration levels (20-900 ppm level). As shown in Table 2.4, the bias 
values (the difference between the measured value and the theoretical value) 
of these 44 solvents are equal or less than ± 2.7% of the theoretical values. 
The results indicate that the HSGC method has sufficient accuracy for 
screening and determining the 44 solvents studied at the working 
concentration level. 
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Table 2.3 Retention times and linearity of 44 ICH class 2 and class 3 
solvents. Reprinted from [65] with permission. 
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Table 2.4 Accuracy and precision of 44 ICH solvents at working 
concentrations. Reprinted from [65] with permission. 
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Table 2.5 Limit of quantitation and limit of detection of 44 ICH solvents. 
Reprinted from [65] with permission. 
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2.3.3.4 Precision 
The precision of the HSGC method was assessed by evaluating both 
method precision (intraday precision) and system repeatability (interday 
precision).  The method precision is presented by the relative standard 
deviation of the response (RSD%, n=6) of six injections (six vials) of the 
same sample (groups I, II and III) at both a working concentration (20-900 
ppm) and a lower concentration (2-90 ppm) on the same day.  The relative 
standard deviations, RSD% of six injections of each solvent in the same day 
(intraday) were in the range of 0.57-2.28% at the 20-900 ppm level and of 
1.56-9.43% at the 2-90 ppm level, respectively, as shown in Table 2.4 and 
Table 2.5. Similarly the relative standard deviations, RSD%, of six injections 
of each solvent in six consecutive days (interday) were in the range of 
0.69-2.19% at the 20-900 ppm level and of 1.44-10.15% at the 2-90 ppm 
level, respectively, as shown in Table 2.4 and Table 2.5. These results 
indicated that this HSGC method has reasonable precision and system 
repeatability within the analytical range of determinations.   
 
2.3.3.5 Method sensitivity 
The sensitivity of this HSGC method is presented as the quantitation 
limit (QL) with a signal-noise ratio of 10 to 1, and detection limit (DL) with 
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a signal-noise ratio of 3 to 1. As shown in Table 2.5, the QL values of the 44 
solvents evaluated range from 0.07-24.70 ppm, and DL range from 0.02-7.41 
ppm. The broad ranges of QL and DL are due to the differences of 
hydrocarbon content in different solvents. Since some elements, e.g., 
chlorine, oxygen and nitrogen, are incombustible, solvents containing these 
elements have lower molar combustion capacities than pure hydrocarbons, 
leading to lower detection limits by FID. However, our results demonstrate 
that this HSGC method is sensitive enough for determination of the 44 
solvents in drug substances, because the QL values (0.07-24.70 ppm) of 
these solvents are much lower than the requirements of ICH guideline for 
class 2 and 3 solvents (50 ppm or higher in most cases). 
 
2.3.3.6 Sample analyses and matrix impacts of drug substances 
In order to demonstrate the suitability of the HSGC method for 
determination of residual solvents in real drug substances, and for evaluating 
the impact of the drug substance matrix on solvent analyses, we analyzed 
four synthesized small molecule organic drug substances from Astrazeneca 
Pharmaceuticals, Wilmington, Delaware. We also spiked the 44 solvents in 3 
groups into the four drug substances at both the 20-900 ppm and 2-90 ppm 
levels. As shown in Figure 2.2 and Table 2.6, the eight solvents in the four 
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drug substances are successfully determined by this HSGC method, and 
these results are consistent with those results from direct injection GC 
methods. When the 44 solvents were spiked into these four drug substances 
at both the 20-900 ppm and 2-90 ppm levels, most of the spiked solvents 
could be recovered from 70% to 115% during the HSGC analysis, as shown 
in Table 2.7, especially at the higher concentrations. These results suggest 
that interferences from the drug substance matrix or from the impurity peaks 
in DMSO, e.g. the peak at 3.1 min, 5.4 min and 14.3 min, should not have a 
significant impact on this HSGC method at regular working concentration. 
However, attention should be paid to those solvents, e.g. methanol (for 
DS1and DS4) and 2-methoxyethanol (for DS1 and DS3), where obvious 
interferences were observed for particular drug substance at the low solvent 
concentration levels. A more specific method validation may be required 
when some solvents recoveries are extremely out of range due to drug 
substances interferences. For example, drug substance samples containing 
hydrocarbon residual solvents (e.g. hexane, pentane, etc.) should be analyzed 
with a smaller sample load, i.e. 20-30 mg, to cover the ICH determination 
range of 5-5000 ppm interest, because these hydrocarbons have lower QLs 
when using FID detection. 
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Table 2.6 Residual solvents in four drug substances. Reprinted from [65] 
with permission. 
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Table 2.7 Recoveries of 44 ICH solvent spiked in four drug substances. 
Reprinted from [65] with permission. 
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2.4 Conclusions 
In this study, a generic HSGC method is successfully developed and 
validated for the determination of 44 ICH Q3C class 2 and 3 residual 
solvents in drug substances. The method is specific, accurate, precise, linear, 
sensitive and efficient. DMSO was selected as the sample diluent due to its 
high capacity for dissolving organic drug substances, stability and high 
boiling point. The conditions of HS sampler and GC were optimized to make 
the HSGC method more sensitive, efficient and reproducible. This method 
has a much shorter sample equilibration time, a better separation for many 
solvents, a higher sensitivity and a broader concentration range comparing 
with the previously published methods. The examples of real drug substance 
analyses demonstrate the broad application potential of this HSGC method in 
the determination of residual solvents in drug substances. This method meets 
ICH guideline requirements, and may be suitable for residual solvent 
determinations in a variety of pharmaceutical applications. 
 
The material in Chapter 2 is adapted from Chang et al. J. Chromatogr. A. 
1217 (2010) 6413. The copyright permission is obtained from Elsevier. 
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Chapter 3: LC-MS/MS for the analysis of highly polar aminoglycoside 
compounds 
 
3.1 Introduction 
The identification and separation of highly polar compounds from 
biomatrices are of great importance in pharmaceutical research and 
development [34,77]. However, LC-MS/MS determination of concentration 
levels of highly polar compounds in biological samples is very challenging for 
the following reasons. First, in sample preparation, the polar nature of these 
compounds makes it difficult for them to be recovered by liquid-liquid 
extraction [78]. Second, in order to obtain best response in MS using positive 
electrospray ionization, it is necessary to keep the mobile phase acidic, which 
causes ionization of basic, polar compounds. In chromatographic separation, it 
is very difficult to achieve proper retention of the ionized polar compounds on 
reversed phase columns; therefore the polar compounds cannot be clearly 
separated from other polar interference peaks and unresolved endogenous 
species in the sample matrix. These drawbacks lead to ion suppression, low 
sensitivity and unreliable quantitation on LC-MS/MS [79,80].  
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The aminoglycoside class of antibiotics is typical highly polar 
compound. This class contains a phamacophoric 1,3-di-aminoinositol moiety, 
whose alcoholic functions are substituted through glycosidic bonds with 
characteristic aminosugars to form pseudo-oligosaccharides [81]. They are 
basic and are free-water soluble at all pH levels. Examples of aminoglycosides 
are: gentamicin, kanamycin, tobramycin, and apramycin. These molecules are 
thermodynamically stable over a wide range of pH values and temperatures 
and have molecular weights ranging from 400 to 500 g/mol. The 
aminoglycosides are basic polycations with pKa values that range from 7.2 to 
8.8 [82]. Among them, gentamicin is one of the most commonly used 
aminoglycoside antibiotics that inhibits both Gram-positive and 
Gram-negative bacteria and is widely used in veterinary medicine to treat 
serious infections [83]. Their toxic effects are related to their levels in blood 
and are mediated by the special affinity of these aminoglycosides for kidney 
cells and sensory cells of the inner ear [84]. Because of the small differences 
between these compounds and the lack of chromophores, LC-MS is the 
analytical method of choice with a detection limits of approximately 400 ng 
once injected onto the column [85]. In order to meet the US Food and Drug 
Administration (FDA) and European Commission (EC)’s established limits of 
tolerance or maximum residue limits for antibiotics in food, an easy and robust 
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LC-MS/MS method must be developed for quantitative analysis of these 
highly polar compounds. This method should also satisfy the analytical need 
of combination antibiotic treatments, which involves aminoglycosides paired 
with compounds from another antibiotic series in order to treat severe 
pseudomonas infections. Several efforts have been made to solve the 
problems of low sample recovery and to achieve improved chromatography 
[33,78,79,86-99].  
One way for polar compounds to achieve great retention is to use a 
hydrophilic interaction chromatographic (HILIC) column, which uses 
unbonded silica silanol or diol bonded stationary phases such as amino, 
anionic, amide, cationic and zwitterionic bonded phases. It was reported that 
using zwitterionic ZIC-HILIC columns interferes with consistent retention 
times for aminoglycoside samples [96]. A large fraction of the recently 
published work has used unmodified bare silica as the separation material 
(Betasil, Hypersil, Kromasil, Atlantis) [31,100]. The separation mechanism of 
HILIC column is that polar analyte partitions into and out of the adsorbed 
water layer allowing the charged polar analyte to undergo cation exchange 
with the charged silanol groups (or other functional groups coated on the silica 
surface). The advantages of underivatized bare silica columns are improved  
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retention of polar compounds, low back pressure with high organic mobile 
phases, and direct injection of organic solvent extracted samples [34]. 
Moreover, non-modified bare silica gel has some advantages for HILIC 
applications in comparison to the chemically bonded stationary phase, as it is 
not subject to bleeding of the bonded phase from the column [101]. It has been 
suggested that a layer of water on the silica surface can act as a deactivating 
reagent on the adsorption site. However, on occasion irreversible adsorption 
has been observed on bare silica in HILIC mode. In order to achieve a lower 
limit of quantitation of 100 ng/mL, 500 L of sample had to be injected [96]. It 
was reported that the elution of some oligosaccharides from HILIC columns 
requires a significant level of salt in the mobile phase. The separation 
mechanism of the HILIC column is a superimposition of electrostatic 
attraction on hydrophilic interactions [29]. Based on the difference of the 
organic modifier, the pH level of the buffer, and ionic strength, the analyte 
gets retained by various mechanisms which could cause double peaks as well 
as increased carryover for highly polar molecules [102]. The combination of 
the mechanism has not been well studied in current literature.  
Another way to increase retention times of polar compounds on 
RPLC is to derivatize the analyte or to add an ion pairing reagent to the 
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mobile phase. Several LC methods have been developed for the analysis of 
aminoglycosides from different biological matrices which involves sample 
derivatization [86,103,104] or addition of an ion pairing reagent to the 
mobile phase [85,87]. While derivatization is a tedious and laborious 
procedure, adding an ion pairing reagent to the mobile phases is a regularly 
practiced technique. With the better penetration and interaction of the 
hydrophobic moiety of the ion pairing reagent, the analyte has better 
retention. For MS purposes, the ion pairing reagents must be volatile and 
easily removed. The most commonly used ion pairing reagents are 
phosphoric acid (H3PO4), alkyl sulfonates, tetra-alkyl ammonium salts [105], 
trifluoroacetic acid (TFA) [106], TCA [91], and perfluorinated carboxylic 
acids with n-alkyl chains [107]. Counter ions can ion pair with basic 
functional groups and impart increased rigidity to the molecule and, in 
addition, exclude these basic groups from the hydrophobic surface of the 
column. The ion pairing reagents bind with the basic or acid functional 
groups and bring these charged basic or acid groups to the hydrophobic 
surface, leading to longer retention times than without ion pairing reagents. 
However, adding ion pairing reagents can often cause the pH of the local 
environment of the analyte to differ from the pH of the mobile phase. That 
change can lead to a more rigid structure of the analyte which leads to a peak 
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sharpening effect. The retention time of an analyte increases as the molecular 
weight of the ion pairing reagent increases. Zhu et al. used 5% TCA with 13 
aminoglycoside compounds and used two HLB SPE cartridges at different 
pH levels to simultaneously purify the compounds and showed a detection 
limit for gentamicin from food of animal origin as 120-140 ng/g [99]. Heller 
et al. used 30% TCA to extract the sample and added 55 mM TFA as an ion 
pairing reagent to the mobile phase A. Using an injection volume of 60 µL, 
they got a 3.3 ng/mL LOQ for gentamicin from bovine plasma [91]. Using 
dual SPE cartridges at extreme pH levels to extract samples and 10 mM 
heptafluoroburyric acid (HFBA) in the mobile phase, Park et al. achieved 
similar detection limits to those demonstrated by Heller [108]. Adding an ion 
pairing reagent often times causes contamination of the ion source and a 
reduction in sensitivity [107]. For example, TFA [108], HFBA [78,89] or 
pentafluoropropionic acid (PFPA) [109] rapidly contaminated the ion source 
and a severe matrix effect was observed [95 ,108]. TCA was reported to be 
used in plasma precipitation at various concentrations and volume ratios to 
samples and also used as an ion pairing reagent in the mobile phase. 
However, when TCA was added to the mobile phase, a two-range standard 
curve had to be calibrated due to the ion suppression effect of TCA [110]. 
Moreover, the effects of TCA concentration on analyte recovery, 
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chromatographic behavior of the analyte, and separation mechanism on silica 
columns were poorly characterized. In our investigation, we studied the 
above issues and developed an easy, robust, and validated LC-MS/MS 
method for quantitative analysis of highly polar aminoglycoside compounds 
in rat plasma. 
 
3.2 Experimental 
3.2.1. Chemicals and reagents  
All solvents used were of HPLC grade and purchased from Fisher 
Scientific (Pittsburgh, PA, USA). Formic acid (88%) was supplied by J. T. 
Baker (Phillipsberg, NJ, USA). 2,2,2-trichloroacetic acid (TCA) (99+%) was 
purchased from Acros (Morris Plains, NJ, USA). Control Rat Plasma in 
K2EDTA (Individual MALE 031-APEK2-MI) was purchased from 
Bichemed (Wichester, MA, USA).  Gentamicin, tobramycin, kanamycin, 
apramycin and ciprofloxacin were obtained from Pfizer Global Research & 
Development (Groton, CT, USA). 
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3.2.2 Equipment 
A standard multi-tube vortex-mixer from VWR Scientific Products 
(West Chester, PA, USA) was used for vortex-mixing, and an Eppendorf 
centrifuge model 5810R from Brinkmann Instruments Inc. (Westbury, NY, 
USA) was used for centrifugation. An Applied Biosystems/MDS Sciex 
(Concord, ON, Canada) model API 4000 triple quadrupole mass 
spectrometer equipped with LC-10AD Prominence solvent delivery system, 
degasser and SCL-10 Avp system controller (Shimadzu, Columnbia, MD, 
USA) was used for LC-MS/MS analysis. A Leap Technologies CTC PAL 
autosampler with Shimadzu 10AD pump was used. A Harvard Apparatus 
(South Natick, MA, USA) syringe pump with a 500 µL syringe from 
Hamilton Co. (Reno, NE, USA) was employed for compound infusion.  
 
3.2.3. Sample preparation using TCA or acetonitrile (ACN) induced 
plasma protein precipitation  
Stock solutions of gentamicin, kanamycin, apramycin and 
tobramycin were prepared as 1 mg/mL in water. Stock solutions were spiked 
in rat plasma to final concentrations of 4000 ng/mL. TCA was diluted in 
water to obtain 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30% and 35% 
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concentration (w/v). For the TCA plasma crash, 30 µL TCA at various 
concentrations was added to 50 µL plasma samples and a white precipitation 
of protein was observed.  Following that precipitation, 170 µL internal 
standard solution of tobramycin at a concentration of 500 ng/mL in water 
was added. Samples were centrifuged at 4000 rpm for 5 minutes before 
aliquoting. For ACN plasma crash, 50-400 µL ACN at various ratios was 
added to 50 µL of the plasma samples and a precipitation of protein was 
observed. Analyte recovery was calculated by peak areas counts ratios with 
samples recovered from plasma and samples from neat solutions. 200 µL 
samples were aliquoted into 1.2 mL polypropylene tubes (96-well format), 
then 10 µL was injected into LC-MS/MS. Samples at each concentration 
level were analyzed in triplicate over three independent batch runs.  
 
3.2.4. Preparation of calibration standards and quality control samples 
Stock solutions of gentamicin, kanamycin, apramycin, tobramycin 
were prepared as 1 mg/mL in water. Tobramycin was further diluted to a 
concentration of 500 ng/mL for using as an internal standard. Stock solutions 
were serially diluted with rat plasma or water. Analytical standards used to 
construct calibration curves were prepared separately for each type of 
extraction method. For plasma and neat samples, standards were prepared by 
 62 
spiking known quantities of the standard solutions into rat plasma and water 
respectively. Serial dilutions were then carried out to achieve desired 
concentrations. Standard reference curves were prepared for analysis in the 
following concentrations: gentamicin, 1, 2, 5, 10, 25, 50, 100, 250, 500, 
1000, 2500 and 5000 ng/mL. For kanamycin and apramycin, 10, 25, 50, 100, 
250, 500, 1000, 2500, 5000, and 10000 ng/mL. Accuracy (% RE) and 
precision (% CV) of the assay were assessed by analyzing 40, 400, 4000 or 
80, 800, 8000 ng/mL quality control samples prepared identically to the 
analytical standards. 
  
3.2.5. LC-MS/MS analysis 
Gradient chromatography was performed using a Synergi 4 m 
Max-RP 80 Ǻ 50 X 2.00 mm C12 column (Phenomenex, Torrance, CA, 
USA) and an Atlantis HILIC Silica 5 m 50 X 2.10 mm column (Waters, 
Milford, MA, USA). Gradient elution was applied with 0.1% formic acid in 
100% water (A) and 0.1% formic acid in 100% ACN (B) at a flow rate of 
0.25 mL/min. The gradient used for the Synergi column was 0.10 min, 5% 
B; 1.50 min, 70% B; 2.50 min, 90% B; 3.50 min, 5% B; 3.6 min, stop. The 
column was equilibrated for 1 minute before beginning the run. The gradient 
 63 
used for the Atlantis column was 0.10 min, 95% B; 1.50 min, 30% B; 2.50 
min, 10% B; 3.50 min, 95% B; 3.6 min, stop. The column was equilibrated 
for 1 minute before run. 
Positive ion electrospray tandem mass spectra were recorded using an 
AB Sciex API 4000 triple quadrupole mass spectrometer with multiple 
reaction monitoring (MRM) detection mode equipped with Analyst (version 
1.41) operating software. The ionspray voltage was set to 5000 V, and the 
probe temperature was set at 500 ℃. Nitrogen was used as the collision gas. 
The nebulizer (GS1), curtain, and turbo gas (GS2) were set to 40, 10, and 50 
psi, respectively. MRM parameters of test compounds were set as described 
in Table 3.1. Dwell times were set to 200 ms for each transition.  
 
3.2.6. Method validation 
Recoveries of the analyte were determined by comparing the peak 
area of five extracted samples of 4000 ng/mL at TCA concentrations of 15%, 
20%, 25%, 30%, 35% (w/v) using the mean peak area of recovery standards. 
Five replicates of each of the recovery standards were prepared by adding the 
analyte to water at the same TCA concentrations.  
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Batches, consisting of triplicate calibration standards at each 
concentration, were analyzed inter and intra day to complete the method 
validation. In each batch, quality control (QC) samples at 40, 400, 4000 or 
80, 800, 8000 ng/mL were assayed in sets of three replicates to evaluate the 
inter and intra day precision and accuracy. The percentage deviation of the 
mean from true values, expressed as relative error (RE), and the coefficient 
of variation (CV) were used as measure of accuracy and precision.  
 
3.3 Results and discussion 
3.3.1. TCA induced plasma protein precipitation  
Plasma protein precipitation with organic solvents is commonly used 
for analyte recovery. However, because polar compounds have a low 
solubility in organic solvents, analyte recovery is very low. Figure 3.1 shows 
analyte recovery for gentamicin, tobramycin and ciprofloxacin versus 
ACN/water volume ratio. The analyte recovery was approximately 20% and 
dropped slightly as the volume ratio increased.  
Figure 3.2 shows analyte recovery for gentamicin, tobramycin and 
ciprofloxacin when various TCA concentrations were used for plasma 
protein precipitation. Ciprofloxacin  was used for comparison purposes 
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[111]. The data shows that analyte recovery increased as TCA concentration 
increased for gentamicin and tobramycin. Since ciprofloxacin is less polar 
(clogD = -0.78 at pH = 6.5) [112] than gentamicin and tobramycin (clogD = 
-8.39 and -9.58 at pH = 6.5) [32,113], its recovery is not as good and 
plateaued from 15 to 30% TCA.  
 
Figure 3.1 Analyte recovery versus ACN/water volume ratio for polar 
small molecules. 
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Figure 3.2 Analyte recovery versus TCA concentration for polar small 
molecules. Reprinted from [66] with permission. 
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The mechanism of TCA-induced protein precipitation was studied 
by Sivaraman [112]. Protein-precipitating action of TCA tends to be 
independent of the nature of the proteins. Acid induced structural transitions 
occur during protein precipitation. The pH is not the dictating force in 
inducing protein precipitation. Acid induced protein precipitation is unique 
to TCA and strongly dependent on the trichloro group. Although blood 
plasma contains not only dissolved proteins, but also glucose, clotting 
factors, mineral ions, hormones and carbon dioxide [114], its TCA induced 
protein precipitation observes a similar phenomenon; at 0.1% and 1% TCA 
concentration, no precipitation was observed and the protein was partly 
changed to molten globule state. Protein precipitation started at 5% TCA, 
and reached a maximum of 30% TCA.  
 
3.3.2 Retention time and hydrophilic interaction chromatographic 
mechanism study on Atlantis HILIC column 
Hydrophilic interaction chromatography is orthogonal to reversed 
phase chromatography and is used to better retain polar compounds. Present 
HILIC theory dictates that HILIC retention is caused by a partitioning of the 
injected analyte solute molecules between the mobile phase eluent and a 
water-enriched layer in the hydrophilic HILIC stationary phase 
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[29-32,77,96,100,113]. The more hydrophilic the analyte is, the more the 
partitioning equilibrium shifts towards the immobilized water layer in the 
stationary phase, and thereby, the more the analyte is retained.  
 
Figure 3.3 shows the chromatograms of gentamicin and tobramycin 
prepared in water with different percentages of TCA. The mobile phase A 
was pure water with 0.1 % formic acid (pH = 2.78) and the mobile phase B 
was 100% ACN with 0.1 % formic acid. Two peaks for each compound were 
observed at different TCA levels. As the percentage of TCA increased, the 
peak area for the first peak increased while the peak area for the second peak 
decreased.  At the same time, the retention times decreased as well. These 
two peaks were due to two separation mechanisms. One separation 
mechanism is the electrostatic interaction or ion exchange between the 
positively charged samples and the negatively charged silanol groups, which 
is correspondent to the first peak.  Another separation mechanism is 
hydrophilic interaction between the neural sample and the water layer 
surface which corresponds to the second peak. When increasing the 
percentage of TCA, the amount of positively charged molecules also 
increases.
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This increase is explained by considering the apparent pKa of 
gentamicin, which is 8.2, and the apparent pKa of tobramycin at 8.0 [30], 
which made the height of the first peak increase. The charge status of the 
aminoglycoside molecules depends on the pKa of amino groups which varies 
depending on their positions from 6.7 to 9.7 [115] as well as the local sample 
pH. With 0.1 % formic acid in the mobile phase, the ionization of silanol 
groups on the silica surface were partly, but not completely, suppressed 
[101], which was why there were electrostatic interactions.  Increasing the 
percentage of TCA also increased the hydrophobicity of the samples, which 
was why the retention times decreased. Though TCA may form ion pairs 
with the sample molecules, it has no impact on retention time change on the 
HILIC column. The main impact of TCA is to change the local sample pH.  
For gentamicin/tobramycin plasma samples , it is useful to consider that 
plasma actually is in a physiological buffer with a pH of 7.4 [116].  The 
charge status of the basic and polar aminoglycoside is determined by the pH 
of the buffer.  At higher TCA levels, when the acidic effect of TCA 
surpassed the buffering capacity, a more of the molecules began to be 
positively charged and the above mentioned first peak began to appear. 
When mobile phase A changed to 10 mM of ammonium acetate in 100% 
water (pH = 6.86), retention times for both compounds shifted slightly to the 
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left. This indicates that dipole-dipole interaction was part of the hydrophilic 
interaction and was weakened by the addition of an electrolyte. The 
appearance of two peaks and the increase of the first peak and decrease of 
the second peak are similar to Figure 3.3, which indicated the same retention 
mechanism.  
 
Figure 3.4 shows the chromatograms of gentamicin/tobramycin 
plasma samples on HILIC column with mobile phase A changed to 10 mM 
ammonium hydroxide in pure water (pH = 10.6). No good chromatograms 
were seen when TCA concentration was greater than 10%. It is seen that the 
retention times for both compounds increased. In general, the pH value of the 
running buffer affects the retention as an ionized molecule is more 
hydrophilic and is retained with more strength in HILIC, than compared to 
its neutral state. In this case, because the sample molecules are already very 
hydrophilic, their ionized form did not show any better hydrophilicity. On 
the other hand, the increase of water phase pH to 10.6 makes the majority of 
silanol groups on the silica surface ionized and negatively charged which 
caused more dipole-dipole interaction and increased the retention times. 
Increasing the level of TCA quickly decreased the peak intensity and caused 
the appearance of another peak which had a shorter retention time.
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Though TCA was an ion paring reagent, the lack of carbon coating 
on the surface did not enable hydrophobic interaction and the separation was 
not based on ion pairing effect. Since there were no hydrophobic interactions 
between the samples and the stationary phase, the forming of ion pairs 
between TCA molecule and sample molecules have no impact on retention 
time change. The driving force for retention time change is pH change. The 
function of TCA was only to change the pH of the sample.  
 
On the whole, the retention and selectivity by HILIC are affected by 
the fraction of organic solvent, the ionic strength and the pH of the buffer. 
Because the bare silica surface is easily charged and the charge status is 
dependent on the pH of the mobile phase, the strong electrostatic interactions 
and dipole-dipole interactions are part of the separation mechanism. The 
charge status of the samples is also a very important factor that determines 
the separation mechanism.  
 
In order to achieve retention of highly polar analytes using RP 
chromatography, non-volatile highly aqueous mobile phases must be often 
used which are not ideal for compound ionization by ESI-MS.  It is 
suggested that HILIC requires mobile phases that are highly volatile and 
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ideal for compound ionization by ESI-MS. However, this is only true when 
isocratic elution was used. In fact gradient elution often times has to be used 
to achieve good peak shape or even to achieve any peak. For RP 
chromatography the volatile component of the mobile phase often times 
reaches to 80-90% when analytes are ionized, while for HILIC it reaches 
5-50%, which doesn’t help ionization efficiency. Moreover, polar biological 
matrices are hard to separate from polar compounds, therefore HILIC 
chromatograph is more subject to potential matrix suppression.  
 
Another issue encountered when using a bare silica column is 
carryover. The adsorption of basic polar analytes on the bare silica surface is 
so strong that the carryover could range from 2% to 50%. The adsorption of 
plasma matrix components to the bare silica surface could change the surface 
charge condition and cover silanol groups, causing complication of 
chromatography. It is well know that basic compounds can interact with the 
unmodified silanols of silica-based columns, resulting in band tailing, poor 
retention and peak shape [107]. 
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3.3.3 Retention time and reversed phase chromatographic mechanism 
study on Synergi Max RP column 
A Synergi Max RP column coated with C-12 was used for RP 
chromatography and to achieve maximum retention. When 0.1% formic acid 
was added to both of the mobile phases, the pH was lowered to 2.78, which 
controlled the ionization situation of the surface silanol groups. Even though 
the silica surface is coated with C-12, approximately 25-50% of the silanol 
groups present on the silica surface are bonded to silanes because of steric 
hindrance. Silanol groups are weakly acidic and depend on the surface 
silanol groups (free silanols, germinal silanols, vicinal silanols) with a  pKa 
range of 2-8 [117]. The effective surface charge is primarily controlled by 
the (de)protonation of the silanol groups [118]. When the pH is equal to 2.78 
there were still parts of the silanol groups that were negatively charged. 
 
The residual surface silanol groups are able to undergo 
hydrogen-bond and dipole-dipole interactions, and when negatively charged, 
electrostatic interactions with polar compounds, which causes peak tailing 
and decreased chromatographic resolutions. In contrast, the charge status of 
gentamicin and tobramycin molecules was controlled by the concentration of 
the TCA that was added to the sample preparation. Figure 3.5 shows the 
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chromatograms of gentamicin and tobramycin neat samples on Synergi 
column (pH = 2.78) with different percentages of TCA. It has been observed 
that when the percentage of TCA concentration is between 0 and 1, there was 
very little retention for gentamicin and tobramycin. 
 
This is not unexpected because there was virtually no hydrophobic 
interaction between the C-12 alkyl chain and the analyte. The hydrogen bond 
and dipole-dipole interactions between the surface silanols and the analyte 
were reduced by the alkyl layer. When the TCA concentration reached 5%, 
some of the gentamicin and tobramycin molecules began to accumulate 
charges, and another peak that had a longer retention time began to appear. 
When the TCA concentration reached 15%, the retention time increased. 
When the percentage of TCA was greater than 20%, a single, sharp peak was 
observed for both gentamicin and tobramycin, indicating the ion pairing 
effect had reached its maximum.  
 78 
 
 
 
 
F
ig
ur
e 
3.
5 
C
hr
om
at
og
ra
m
s 
of
 G
en
ta
m
ic
in
/T
ob
ra
m
yc
in
 n
ea
t 
sa
m
pl
es
 o
n 
Sy
ne
rg
i c
ol
um
n 
(p
H
=
2.
78
),
 T
C
A
 C
ra
sh
 
 79 
 
 
 
 
 
F
ig
ur
e 
3.
6 
C
hr
om
at
og
ra
m
s 
of
 G
en
ta
m
ic
in
/T
ob
ra
m
yc
in
 p
la
sm
a 
sa
m
pl
es
 o
n 
Sy
ne
rg
i c
ol
um
n 
(p
H
=
2.
78
),
 T
C
A
 C
ra
sh
. R
ep
ri
nt
ed
 f
ro
m
 [
66
] 
w
it
h 
pe
rm
is
si
on
. 
 80 
 
Figure 3.6 shows the same experiments related to gentamicin and 
tobramycin plasma samples. When the TCA concentration was higher than 
10%, not only could it precipitate proteins in plasma, but also it had the same 
effect of increasing the retention time. When the retention time was 
increased, the peaks did not become wider but narrower; therefore TCA also 
had the effect of sharpening the peaks. Increasing retention time also made it 
possible to separate the analyte from the sample matrix, which was 
composed primarily of protein residues and salts. In contrast, when no TCA 
was used and the retention time was low, the analyte peak intensity was 
subject to the matrix effect, and was significantly lower. Because TCA was 
added to the samples but not the mobile phase, it was ion paired with the 
analyte and helped to increase the retention of the analyte but it didn’t have 
the signal suppressing effect of ion pairing reagent added to the mobile 
phase. When compared with the commonly used perfluorinated carboxylic 
acids with alkyl chains, TCA disassociated easily with the analyte and as its 
concentration increased the signal counts increased as well. When no TCA 
was used but ACN was used for neat samples, no analyte precipitation was 
observed and the peak intensity counts for the analyte remained almost the 
same (data not shown). However, when ACN was used for plasma protein 
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precipitation as the ratio of ACN/water increased, the peak intensity counts 
decreased, which suggested that more analyte precipitated with proteins 
when the ratio of ACN increased.  
 
3.3.4 Quantitation 
3.3.4.1. HILIC  
The calibration curve of gentamicin/tobramycin plasma samples over 
the range of 20-5000 ng/mL without use of an ion pairing reagent on the 
Atlantis HILIC column with 10 mM ammonium acetate buffer is shown in 
Figure 3.7. A non-linear fitting, as the concentration increases suggests that 
irreversible adsorption happened during the sample preparation and sample 
analysis. The adsorption to the silica column is the dominant reason since 
same samples produce a linear curve when analyzed with a reversed phase 
column. The LLOQ was 20 ng/mL, which was not as good as the LLOQ 
obtained from reversed phase chromatography as discussed below.  
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Figure 3.7 Calibration curve of Gentamicin plasma samples without ion 
pairing reagent on Atlantis HILIC column (10 mM ammonium acetate 
buffer) 
 
3.3.4.2. Reversed phase chromatography: 
The calibration graph shown in Figure 3.8 for gentamicin was 
generated from MRM analysis of five replicate rat plasma samples at the 
calibration standard concentration level over the range of 1-5000 ng/mL, 
with tobramycin as the internal standard at 500 ng/mL. Kanamycin and 
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apramycin were prepared in the same manner as gentamicin except the range 
was 10-10000 ng/mL.  
 
Figure 3.8 Calibration curve of Gentamicin plasma samples with 
30%TCA on Phenomenex Max-RP column (0.1% formic acid in mobile 
phase)  
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Figure 3.9 LLOQ of Gentamicin plasma sample is 1 ng/mL. 
 
With an injection volume of 10 µL, good responses over the 
concentration ranges were obtained. Calibration curve regression was 
weighed as 1/x and performed using linear fit of quantities versus peak area 
ratios. Precision and accuracy data are shown in Table 3.2. The LLOQ 
corresponding with a coefficient of variation less than 20% was 1, 20 and 10 
ng/mL for gentamicin, kanamycin and apramycin, respectively. Figure 3.9 
shows the chromatogram of the LLOQ of gentamicin. The standard 
calibration curves were linear over the concentration range with a correlation 
coefficient better than 0.9993.   The precision was over the range of 
2.6-4.1, 3.3-5.0, 1.5-9.9%, and accuracy was 94.7-103.7, 87.9-104.9, 
91.3-103.6% for gentamicin, kanamycin and apramycin respectively. Since 
TCA was only added to samples but not to the mobile phase, no ion 
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suppression was observed which would cause the non-linearity of the 
standard curve. The LLOQ is much lower than can be achieved with ion 
pairing chromatography using perfluorinated carboxylic acids ion-pairing 
reagent and HILIC columns. 
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3.3.5 Real Sample Analysis 
Aminoglycoside compounds alone or in combination with other antibacterial 
compounds were used for intravenous (IV) dose of bacterial infected rats to obtain 
their pharmacokinetic and pharmacodynamic (PK-PD) profiles and to discover their 
synergetic effect against Gram-negative bacteria. The dose level was 2 mg mL-1 kg-1 
compound in normal saline. Whole blood samples were collected at 5 min, 15 min, 30 
min, 1 hr, 2 hr, 4 hr, 8 hr and 24 hr and processed to plasma by centrifugation. Figure 
3.10 shows the chromatogram of gentamicin plasma sample collected at 4 hr time 
point.  
 
 
Figure 3.10 The chromatogram of gentamicin plasma sample collected at 4 h 
after IV dose of gentamicin at 2 mg/mL• kg. Reprinted from [66] with 
permission. 
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3.4. Conclusions 
In this project, we have studied the effect of the concentration of TCA on 
plasma protein precipitation and sample recovery efficiency. It was found that the 
TCA sample crash method gives better sample recovery than the ACN sample crash 
method when the concentration of TCA reach 25-30% for polar small molecules. It 
can be concluded that the TCA sample crash method is a general sample preparation 
method for polar compounds such as aminoglycosides. Moreover, when TCA is used, 
it has the effect of increasing the retention of highly polar small molecules such as 
gentamicin and tobramycin as well as sharpening the elution peaks. 
 
By studying the retention behavior of gentamicin and tobramycin on a HILIC 
column, the mechanism of analyte interaction with a silica surface was further 
understood. The charge status of the silica surface is dependent on the pH of the 
running buffer. The TCA concentration, on the other hand, determines the charge 
status of the analyte and the pH of the injected sample. The charge status of the 
analyte and the charge of silica surface together determine the chromatographic 
behavior.  
 
An LC-MS/MS method has been developed and validated for the analysis of 
gentamicin, kanamycin and apramycin with tobramycin as the internal standard. The 
method used TCA protein precipitation, a reversed phase C-12 column and a very 
high aqueous content buffer to afford enough retention of gentamicin. A satisfactory 
LLOQ of 1 ng/mL and standard curve was obtained when injection volume is 10 µL. 
Compared with existing methods, our method avoided using ion pairing reagent in the 
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mobile phase, yet it yielded comparable or better sensitivity for the compounds 
studied than using various ion pairing agent in the mobile phase or using HILIC 
columns.  
 
The material in Chapter 3 is adapted from Chang et al. Chromatographia 72 (2010) 
133. The copyright permission is obtained from Springer. 
 
 90 
Chapter 4: LC-MS/MS for the determination of polymyxins and vancomycin in 
rat plasma 
 
4.1. Introduction 
In the past 30 years, the emergence of multi-drug resistance (MDR) bacteria has 
created a situation in which there are few or no treatment options for infections by 
certain microorganisms. For example, the emerging MDR Gram-negative bacteria, 
Pseudomonas aeruginosa and Acinetobacter baumannii, are resistant to all β-lactams, 
fluoroquinolones, and aminoglycosides [119,120]. Additionally, methicillin resistant 
Staphylococcus aureus (MRSA) has evolved into a significant pathogen among 
hospitalized patients around the world [121]. Lipopeptide Polymyxins (PMXs) and 
glycopeptide vancomycin (VCM) interact noncovalently to their target ligands, 
usually cell-wall or cell-membrane structures. As the noncovalent interactions are 
nonspecific than covalent interactions, it is more difficult for bacteria to develop 
resistance to these agents [122]. This mechanistic opportunity is used in developing 
antibacterial peptide drugs against MDR bacteria [123]. This has led to the resurgence 
in the use of PMX antibiotics which are active against a wide spectrum of 
Gram-negative bacteria despite their known nephrotoxicity [124,125]. Moreover, 
there exist renewed interests in the exploration of VCM and other glycopeptide 
modifications that are active against Gram-positive bacteria [126].  
 
The two clinically used PMXs, PMB and PME (Structure shows in Table 4.1), 
are cyclic lipodecapeptides. In these peptides, the amino acid units 1-3 are linear and 
4-10 form a 23-membered ring. Each molecule carries 5 free amino groups and, 
accordingly, 5 positive charges are present under physiological conditions [127]. The 
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main difference between PMB and PME is in the amino acid components. PMB is 
comprised mainly of PMB1 and PMB2 [128], and PME (also known as colistin), is 
comprised mainly of PME1 (colistin A) and PME2 (colistin B) [129,130]. The 
cationic molecules of PMX compete and displace Ca2+ and Mg2+ ions, and the 
hydrophobic segments of PMX microscopically form complexes with bacterial 
lipopolysaccharide, which causes local disturbance of the cell membrane, and 
increases cell permeability, cell lysis and death [131-134]. They display 
sub-micromolar minimum inhibitory concentration (MIC) values against a variety of 
Gram-negative bacteria [120,124,126,127,135,136].  
 
Currently there is a lack of reliable information concerning the 
pharmacokinetic data for PMXs in humans [120,128]. PMXs are highly soluble in 
water and poorly soluble in organic solvents [137]. The unique molecular properties 
of PMXs present chromatographic challenges with a variety of conventional reverse 
phase LC columns. Since all the main components of the PMXs possess five free 
amino groups which tend to adsorb onto silica surface [138], severe peak tailing is 
observed for untreated PMX samples with LC. Therefore, either derivatization [139] 
or further purification are required for optimal bioanalysis. Bioanalytical methods 
such as capillary zone electrophoresis (CZE) [140,141], high-performance liquid 
chromatography (HPLC) with fluorescence detection, UV spectrophotometric 
detection or scanning fluorescence detection [139,142,143], and LC-MS/MS 
[144,145] have been used for quantitative analysis. Since CZE and LC with UV and 
fluorescence detection lack structure-specific selection [142], and fluorescence 
detection requires compound derivatization for a sensitive and specific method 
[102,139,142,143], LC-MS/MS is the choice for pharmaceutical industry because of 
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its high sensitivity and structural specificity. The reappraisal of PMXs as the only 
available active antibiotics for some bacteria species as well as the combined-drug 
synergy study of PMXs with other antibacterial compounds [120] demand a simple 
and accurate analytical method with adequate dynamic range and sensitivity for the 
determination of PMXs in biological samples. 
 
Recently, LC-MS/MS methods have been developed for quantification of 
PME (colistin) in milk and animal tissues [145,146]. The methods required the use of 
strong and highly concentrated acids for sample recovery followed by laborious 
sample clean-up, preconcentration, and long separation time. LC-MS/MS methods 
have also been reported for the analysis of PME in human plasma and urine 
[144,147]. These methods are unsatisfactory since they require a long and expensive 
procedure of SPE, consumption and injection of a large volume of samples (100-200 
µL), and long separation time with poor chromatography. The reported sensitivity for 
PME in any matrices ranges from 30-300 ng/mL (g) per 10 µL injection.  
 
Another class of antibiotic peptide drugs is glycopeptide antibiotics. This class 
is composed of glycosylated cyclic or polycyclic nonribosomal peptides, neutral 
sugars and an amino sugar. The peptides consist of cross-linked unusual aromatic 
amino acids and conventional amino acids such as aspartic acid [148]. Significant 
glycopeptide antibiotics include VCM, dalbavancin, teicoplanin, telavancin, 
bleomycin, ramoplanin, and decaplanin [149,150]. They are soluble in aqueous 
solvent but not in nonpolar organic solvents. This class of drugs inhibits the synthesis 
of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis. They bind 
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to the amino acids within the cell wall, preventing the addition of new units to the 
peptidoglycan. 
 
VCM is a benchmark compound for various preclinical pharmacology models 
treating endocarditis [151,152]. However, the unique molecular properties of VCM 
presented similar bioanalytical challenges as PMXs. Current LC-MS methods include 
using strong cation exchange SPE for sample preparation from serum followed by 
LC-full scan Fourier transform MS [153], online sample extraction followed by 
column switching technique [154], and an offline sample extraction technique using 
TFA and methanol [155]. The LLOQ obtained ranged from 1 to 10 ng/mL. The above 
methods require complicated extraction procedure, large injection volume and long 
separation time. Moreover, the previous studies didn’t apply sample recovery 
optimization.  
 
The two classes of antibiotics, lipopeptide PMXs and glycopeptide VCM, 
actually have similarities. They are both peptide drugs of similar molecular weight 
range; the sizes of the peptide parts are dominant in either the lipopeptide molecules 
or in the glycopeptide molecule. The purpose of the study is to develop and validate a 
general bioanalytical method based on the same principle for the above antibacterial 
peptide compounds.  
 
4.2. Experimental 
4.2.1 Chemicals and reagents  
All solvents used were of HPLC grade and purchased from Fisher Scientific 
(Pittsburgh, PA, USA). Formic acid (88%) was supplied by J. T. Baker (Phillipsberg, 
 94 
NJ, USA). TCA (99+%) was purchased from Acros (Morris Plains, NJ, USA). 
Control Rat Plasma in EDTA K2 (Individual MALE 031-APEK2-MI) was purchased 
from Bichemed (Wichester, MA, USA). PMB (polymyxin B sulfate), PME (colistin 
methanesulfonate), VCM and dalbavancin were obtained from Pfizer Global Research 
& Development (Groton, CT, USA). [Glu1]-Fibrinopeptide B human (≥97%) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
4.2.2 Equipment  
A standard multitube vortex-mixer from VWR Scientific Products (West 
Chester, PA, USA) was used for vortex-mixing, and an Eppendorf centrifuge model 
5810R from Brinkmann Instruments Inc. (Westbury, NY, USA) was used for 
centrifugation. An Applied Biosystems/MDS Sciex (Concord, ON, Canada) model 
API 4000 triple quadrupole mass spectrometer equipped with a Shimadzu LC-10AD 
Prominence solvent delivery system, degasser and SCL-10 Avp system controller 
(Columnbia, MD, USA) was used for LC-MS/MS analysis. A Leap Technologies 
CTC PAL autosampler with Shimadzu 10AD pump was used. A Harvard Apparatus 
(South Natick, MA, USA) syringe pump with a 500 µL syringe from Hamilton Co. 
(Reno, NE, USA) was employed for compound infusion.  
 
4.2.3 Sample preparation using TCA or acetonitrile (ACN) induced plasma 
protein precipitation  
For TCA induced plasma precipitation, TCA was diluted in water to obtain 
0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30% and 35% concentration (w/v). To 50 µL 
plasma samples, 30 µL TCA at various concentrations were added; white protein 
precipitation was observed; then 170 µL water was added. Samples were centrifuged 
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at 4000 rpm for 5 minutes, and 50 µL of the supernatants were aliquoted into a 1.2 
mL polypropylene 96-well plates for sample analysis. For ACN induced plasma 
precipitation, to 50 µL plasma samples, 25-200 µL ACN (at various ACN/water ratios) 
were added to 50 µL of plasma samples, and protein precipitation was observed. 50 
µL of the supernatants were aliquoted and reconstituted in 10% ACN for sample 
analysis. Analyte recovery was calculated by peak areas count ratios of samples 
recovered from plasma and samples from water solutions at correspondent TCA 
concentrations. Samples at each concentration level were analyzed in triplicate over 
three independent batch runs.  
 
4.2.4 Preparation of calibration standards 
Stock solutions of PMB (containing PMB1 and PMB2), PME (containing 
PME1 and PME2), Fibrinopeptide B, VCM and dalbavancin were prepared as 1 
mg/mL concentration in water with their purity factors considered. Fibrinopeptide B 
and dalbavancin were further diluted to 500 ng/mL for use as internal standards for 
PMXs and VCM, respectively. Stock solutions were serially diluted with rat plasma 
or water. Analytical standards used to construct calibration curves were prepared 
separately for each type of extraction method. The stock solutions of the compounds 
were prepared in water and the stock standard solutions were carried out by serial 
dilutions of the stock solutions to desired concentrations. Plasma and neat solvent 
working standards were prepared by spiking known quantities of the stock standard 
solutions to the blank rat plasma and water, respectively. The final concentrations for 
PMXs working standards are: 5, 10, 25, 50, 100, 250, 500, 1000, 2500, 5000 ng/mL; 
for VCM: 1, 2, 5, 10, 25, 50,100, 250, 500, 1000, 2500, 5000 ng/mL. Accuracy (% 
RE) and precision (% CV) of the assay were assessed by analyzing quality control 
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samples of 19.5, 156, 1250 ng/mL for PMB1 and PME1 and 39.1, 313, 2500 ng/mL 
concentration for PMB2, PME2 and VCM. Quality control samples were prepared 
identically to the analytical standards. 
  
4.2.5 LC-MS/MS analysis 
A Phenomenex Jupiter C18 5μ 300 Å 50x2 mm column (Torrance, CA, USA) 
was used for the analysis. Gradient chromatography was performed with 0.1% formic 
acid in 100% water (A) and 0.1% formic acid in 100% ACN (B) at a flow rate of 0.25 
mL/min. The gradient used was 0-0.5 min, 5% B; 1.5 min, 70% B; 2.5 min, 90% B; 
3.0-3.5 min, 5% B; 3.6 min, stop. The injection volume was 10 µL. To test the impact 
of the silica pore size of the column with VCM, isocratic elution was applied at 6% B 
with 0.1 % acetic acid. The column was equilibrated for 1 min before each run. 
Positive ion electrospray tandem mass spectra were recorded using an AB 
Sciex API 4000 triple quadrupole mass spectrometer with multiple reaction 
monitoring (MRM) detection mode controlled by Analyst (version 1.41) operating 
software. The ionspray voltage was set to 5000 V, and the probe temperature was set 
at 500 ℃. Nitrogen was used as the collision gas. And the nebulizer (GS1), curtain, 
and turbo gas (GS2) were set to 40, 10, and 50 psi, respectively. MRM parameters of 
test compounds were set as described in Table 4.1. Dwell times were set to 200 ms for 
each transition.  
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4.3. Result and discussion 
4.3.1 TCA Induced Plasma Protein Precipitation  
Plasma protein precipitation with organic solvents is commonly used for 
analyte recovery. However, because of the very low solubility of the peptide 
compounds in organic solvents, their analyte recoveries were less than 20% at various 
ACN/water volume ratios (0.5:1, 1:1, 2:1, 4:1). In order to obtain better recoveries for 
high throughput liquid-liquid extraction methods, chlorine-containing acid induced 
protein precipitation had been used. In our research, we choose TCA over HCl or 
HClO4 since it was studied that protein precipitation is not dictated by pH but is 
strongly dependent on the trichloro group [112]. No precipitation was observed at 
0.1% and 1% TCA concentration, but the protein was partly changed to a molten 
globule state. Protein precipitation initiated at 5% TCA, and reached a maximum at 
about 30% TCA. Figure 4.1 shows analyte recovery for PMB, PME, Fibrinopeptide B 
and VCM when various TCA concentrations were used for plasma protein 
precipitation. The data shows that analyte recoveries increased as TCA concentration 
increased for all the peptides. Since VCM is less polar than PMX, its recovery 
plateaued about 15 to 35% TCA. For PMX the analyte recoveries surpassed 100% 
when TCA concentration was higher than 20%, which indicated that adding TCA not 
only helped protein precipitation but also helped to increase the mass spectrometric 
response of PMX. It was determined 30% TCA was the concentration to optimize 
analyte recoveries.  
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Figure 4.1 Analyte recovery versus TCA concentration for peptide molecules. 
Reprinted from [67] with permission. 
 
4.3.2 Chromatographic Conditions Optimization 
One important aspect of liquid chromatography separation involves matching 
the pore size of the packed silica with the size of the analyte molecules. Several 
columns with different pore sizes had been tested with VCM as shown in Table 2. It 
was found that amongst important column retention parameters such as carbon load, 
surface area, coverage, and pore size, increasing pore size can improve peptide 
retention while holding other parameters constant. The molecular weights (MW) of 
the antibacterial peptide compounds are greater than 1000 Da and the Phenomenex 
Jupiter C18 5μ 300 Å 50x2 mm column was selected for LC-MS/MS analysis. PMX 
molecules were also tested, and the Phonomenex column was found to offer the best 
performance.  
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Table 4.2 Column parameters versus retention times for VCM. Reprinted from 
[67] with permission. 
 
 
For PMX, the chromatography was optimized by employing a gradient elution 
that started at a very low ACN percentage (5%) where it was held for 0.5 min to allow 
the analyte to achieve good retention. After 1.5 min, ACN percentage was increased 
to 90%, as high organic content helped the analyte achieve better ionization 
efficiency. Figure 4.2 shows the effects of TCA concentration on retention of PMB1, 
PME1 and VCM (the data for PMB2 and PME2 were very similar to PMB1 and 
PME1 and are not shown) in both neat (water) solution [Figure 4.2(a)] and in rat 
plasma [Figure 4.2(b)]. In both matrices, increasing the TCA percentage (only added 
in the samples) from 5% to 20% quickly increased the retention time of the PMXs and 
VCM until the retention time remained steady after 20% TCA. The increase of the 
retention time is derived from the ion-pairing effect of TCA. When TCA was added to 
the samples during sample preparation, TCA formed ion pairs with the polar 
molecules, increased their hydrophobicity, changed their charge status, and changed 
the interaction between the analyte and the column surface. When the percentage of 
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TCA was greater than 20%, a single, sharper peak was observed for both PMB1 and 
PMB2 compared to not adding TCA, indicating the ion pairing effect had reached its 
maximum. It was also seen that the buffering capacity of the plasma supernatant had 
reduced the retention differences between PMX and VCM.  
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Figure 4.2 The effect of TCA concentration on retention of PMB1, PME1 and 
VCM tested with gradient elution in (a) neat solution; (b) rat plasma. Reprinted 
from [67] with permission. 
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To determine the ratios of PMB1 to PMB2 and PME1 to PME2, it was 
assumed that analyte pairs have the same response factor for MRM detection. This is 
reasonable since the molecules differ by a single CH2 group [144,145,156]. As 
purified PMB1, PMB2, PME1 and PME2 are unavailable and their compositions 
differ between manufacturers and batches, the percentage of the components were 
determined by their peak area ratios with respect to the total peak area. The 
percentage of PMB1 and PMB2 was found to be 78.0 ± 0.8% and 17.0 ± 0.8%. The 
percentage of PME1 and PME2 was found to be 71.0 ± 1.1% and 24.0 ± 1.1%.  
 
4.3.3 Quantitation 
The calibration curves for PMXs were generated from MRM analysis of five 
replicate rat plasma samples at the calibration standard concentration level covering 
the range of 5-5000 ng/mL, with Fibrinopeptide B as the internal standard at 500 
ng/mL and an injection volume of 10 µL. VCM was prepared in the same manner as 
PMXs except the concentration range was 1-5000 ng/mL, with dalbavancin as the 
internal standard. Good responses over the concentration ranges were obtained. 
Calibration curve regression was weighted as 1/x and analyzed using linear fit of 
quantities versus peak area ratios. Precision and accuracy data are shown in Table 3. 
The standard calibration curves were linear over the concentration range with a 
correlation coefficient better than 0.9989. The method validation yielded precision 
results of: 4.3-7.4, 2.3-9.2, 5.1-10.8, 3.8-9.4, and 7.8-10.3% and accuracy results of: 
91.7-104.2, 91.7-105.1, 94.9-104.8, 94.3-107.4%, and 96.2-102.0% for PMB1, 
PMB2, PME1, PME2, and VCM, respectively. The LLOQs corresponding to a 
coefficient of variation less than 20% were 7.5, 18.1, 7.3, 5.0 and 1.0 ng/mL for 
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PMB1, PMB2, PME1, PME2 and VCM, respectively. Since TCA was only added to 
the samples but not to the mobile phases, the ion suppression which would cause the 
non-linear standard curves was not observed. The data demonstrated that good 
accuracy and precision of this assay was developed for rat plasma samples. This is a 
significant improvement over assays reported in the literature in terms of sensitivity, 
simplicity and understanding of the chromatography challenges for both PMXs 
[145,146] and VCM [153]. For PMXs the reported methods require a long and 
expensive procedure of SPE, consumption and injection of a large volume of samples 
(100-200 µL), and long separation time (7-16 mins) with poor chromatography (peak 
tailing and peak fronting) and low sensitivity (For PME in any matrices ranges from 
30-300 ng/mL (g) per 10 µL injection).Similarly for VCM our method avoided 
complicated extraction procedure, large injection volume, or long separation time, yet 
it achieved better or similar sensitivity than the literature reports (1-10 ng/mL). 
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4.3.4 Real Sample Analysis 
PMB and PME were administrated individually though intravenous 
(IV) route into the tail vein of Sprague-Dawley (SD) rats to obtain their 
pharmacokinetic profiles. The dosed amounts were 0.2, 0.4 and 2 mg/kg of 
compound in sterile saline. VCM were administrated individually via 
subcutaneous (SC) route into bacterially infected Sprague-Dawley (SD) rats 
in order to obtain the pharmacokinetic and pharmacodynamic (PK-PD) 
profiles. The dose amounts were 20, 60, and 200 mg/kg in sterile saline. 
Whole blood samples were collected at 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 
hr, 8 hr and 24 hr and processed by centrifugation to obtain plasma. Figure 
4.3(a) shows the chromatograms for PMB1 and PMB2, Figure 4.3(b) for 
PME1 and PME2, and Figure 4.3(c) for VCM plasma sample collected at the 
4 hr time point when the dose amounts for PMB and PME were 2 mg/kg and 
for VCM was 200 mg/kg. 
 110 
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Figure 4.3 The chromatograms of peptide drugs rat plasma sample 
collected at 4 hr (a) PMB1 and PMB2, after IV dose of PMB at 2 mg/kg; 
(b) PME1 and PME2, after IV dose of PME at 2 mg/kg; (c) VCM, after 
SC dose of VCM at 200 mg/k. Reprinted from [67] with permission.  
 
4.4. Conclusions 
In the present work, we have studied the effect of the concentration of 
TCA on plasma protein precipitation and sample recovery efficiency for 
antibacterial peptide compounds. It was found that the TCA sample 
precipitation method gave better sample recovery than the ACN sample 
precipitation method when the concentration of TCA reached 25-30% for 
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these polar peptide molecules. It can be concluded that the TCA sample 
precipitation method is a general sample preparation method for hydrophilic 
peptide compound with MW less than 2000 Da. Moreover, when TCA is 
used, it has the effect of increasing the retention of the peptide molecules as 
well as sharpening the elution peaks. LC-MS/MS methods have been 
developed and validated for the analysis of PMB and PME with 
Fibrinopeptide B as the internal standard and VCM with dalbavancin as the 
internal standard. The method used TCA protein precipitation, a reversed 
phase C-18 column with pore size of 300 Å, and a very high aqueous content 
buffer to afford acceptable retention. Satisfactory LLOQs of 7.5, 18.1, 7.3, 
5.0 and 1.0 ng/mL for PMB1, PMB2, PME1, PME2 and VCM, respectively, 
were obtained using an injection volume of 10 µL. Compared with existing 
methods, the method detailed in this paper avoided using ion pairing reagents 
in the mobile phase, derivatization, SPE, organic solvent extraction and long 
separation time, yet it yielded similar or better sensitivity for the compounds 
studied.  
 
The material in Chapter 4 is adapted from Chang et al. J. Chromatogr. B. 
878 (2010) 2831. The copyright permission is obtained from Elsevier. 
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Chapter 5: Development and validation of an efficient liquid 
chromatography-tandem mass spectrometry method for determination 
of fifteen estrogens and metabolites in human serum  
  
5.1 Introduction 
Endogenous female hormones are important indicators in human 
physiology and pathology. Determination of estrogens and metabolites is one 
of the most critical steps in human physiological and pathological diagnosis, 
especially in risk assessment of certain cancers. Bioanalytical method 
development and validation plays an essential role in analyzing female 
hormones, e.g. estrogens and metabolites in human blood, urine and tissues, 
because it is very challenge to determine endogenous estrogens and 
metabolites accurately at extremely low levels, e.g. pg/mL or pmol/L. 
Varieties of bioanalytical techniques or methodologies have been developed 
and applied for analyzing estrogens and metabolites, such as 
radioimmunoassay, LC-MS/MS, GC-MS/MS [157-160], and liquid 
chromatography with electrochemical detection (HPLC/ECD) [161]. The 
method specificity and sensitivity are the major advantages of LC-MS/MS 
and GC-MS/MS over radioimmunoassay and HPLC/ECD.  
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A large number of LC-MS, GC-MS, LC-MS/MS and GC-MS/MS 
methods for determination estrogens and metabolites have been published in 
the past. The bioanalytical methods developed in recent years focused more 
on LC-MS/MS and GC-MS/MS techniques, because the earlier studies 
demonstrated that LC-MS and GC-MS were significantly less sensitive in 
analyzing estrogens and metabolites than LC-MS/MS and GC-MS/MS 
[159,162]. It was obvious that those LC-MS/MS methods directly analyzing 
biological samples containing estrogens and metabolites were simple and 
straightforward [163-167]. However, a number of studies demonstrated that 
the LC-MS/MS methods directly analyzing estrogens and metabolites were 
significantly less sensitive than those methods analyzing chemically 
derivatized estrogens and metabolites [157,168-170], because the neutral 
molecules of estrogens and metabolites might not be effectively ionized 
under electrospray ionization (ESI) or atmospheric pressure chemical 
ionization (APCI) modes. Therefore, chemical derivatization became an 
important sample preparation procedure for estrogens and metabolites before 
LC-MS/MS analysis.    
 
An ideal derivatization reagent should react with estrogens and 
metabolites selectively and quantitatively under mild conditions within a 
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short time, and those estrogen derivatives should be stable and easily ionized 
during LC-MS/MS analysis. There were mainly five classes of reagents used 
for derivatizating estrogens and metabolites, including: 1) sulfonyl cholride, 
e.g. dansyl chloride, 1,2-dimethylimidazole-4-chloride and 
pyridine-3-sulfonyl chloride; 4-(1-H-pyrazol-1-yl)benzenesulfonyl chloride 
[171]; 2) carbonyl chloride or carboxylic acid N-hydroxysuccinimide ester, 
e.g. picolinoyl chloride [172] and N-methyl-nicotinic acid 
N-hydroxysuccinimide ester [170]; 3) benzyl bromide, e.g. 
pentafluorobenzyl bromide [169,173] and 4-nitrobenzyl bromide [174]; 4) 
fluorobenzene or fluoropyridine, e.g. 2,4-dinitro-5-fluorobenzene analogues 
[168] and 2-fluoro-1-methyl-2-pyridinium p-toluensulfonate [43] ; and 5) 
hydrazide, e.g. (Carboxymethyl)trimethylammonium chloride hydrazide 
(Girard T reagent) [157,175], and  p-tolune sulfonhydrazide [176].  
 
In contrast to the sulfonyl chloride, carbonyl chloride, benzyl 
bromide and fluorobenzene reagents, the hydrazide reagents reacted only 
with ketolic estrogens and metabolites. They seemed suitable for certain 
estrogens, but not for determining all the estrogens and metabolites at the 
same time, because those alcoholic estrogens and metabolites, e.g. estradiol 
and estriol, were excluded from the related analytical methods 
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[157,175,176]. Pentafluorobenzyl bromide estrogen derivatives were 
sensitive to both ESI+ [173] and APCI- [43,169] modes, and these derivatives 
had lower limits of quantitation (LOQ) values under APCI- mode than the 
LOQ values of derivatives of dansyl chloride and 
2-fluoro-1-methyl-pyridinium p-toluenesulfonate under ESI+ mode, because 
there were less interferences from analogue compounds and the matrix 
background under APCI- mode. Nevertheless, the dervatization reaction of 
estrogens with pentafluorobenzyl bromide was ten times longer than the 
dervatization reaction with dansyl chloride (30 min vs. 3 min at 60 ºC) [43].  
A study by Higashi et al. indicted that the derivatization reaction of 
estrogens with 4-nitrobenzene sulfonyl chloride was the most complete and 
quantitative in comparison to those reactions with 4-nitrobenzoyl chloride, 
4-nitrobenzyl bromide, 2,4-dinitro-fluorobenzene. In addition, the reaction 
with 4-nitrobenzoyl chloride was lack of selectivity, because it could react 
with both phenolic and alcoholic hydroxyl groups of estrogens at the same 
time, whereas 4-nitrobenzyl bromide, 2,4-dinitro-fluorobenzene and 
4-nitrobenzene sulfonyl chloride reacted with phenolic hydroxyl group only 
[174].  These results implied that a sulfonyl chloride was a preferred 
reagent for derivatizing estrogens and metabolites, due to its reaction 
completeness and selectivity. Further, a sulfonyl chloride reagent containing 
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a basic or preionzed nitrogen atom, e.g. on dansyl molecule or on a pyridine, 
imidazole, pyrazole or piperizine ring, could significantly enhance the 
ionization of estrogen derivatives under ESI+ mode, and increase the 
detection sensitivity [157,168,171].    
 
Dansyl chloride was a typical sulfonyl chloride reagent used for 
derivatizing estrogens and metabolites from varieties of matrix, such as river 
water [43], charcoal-stripped fetal bovine serum [171], mouse plasma and 
brain [177], human urine [178,179], breast tissue [180], and serum [181]. 
Since most of the endogenous estrogens and metabolites exist as glucuronide 
and sulfate conjugates, and these conjugates should be hydrolyzed by 
β-glucuronidase and sulfatase before derivatization. Xu and colleagues 
published a number of LC-MS/MS methods for determination of fifteen 
dansylated unconjugated estrogens and metabolites in urine and serum 
[8,179-181].  However, these methods had a very long elution time, 100 
minutes, which significantly affected the method throughput.  In addition, 
even the 75 min gradient for the Phenomenex Synergy Hydro-RP 4 µm 
column (150 x 2.0 mm) was insufficient to separate all the fifteen dansylated 
estrogens and metabolites.         
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In this study, we developed a method providing a better separation with 
a significantly shorter elution time. The method eluted a Phenomenex 
Synergi Hydro-RP 2.5 µm column (100 x 2.0 mm) at a higher temperature 
with the mobile phases consisting of acetonitrile, methanol, water and formic 
acid at a faster flow rate. We also attempted to optimize the dansyl 
derivatization procedures and the detection sensitivity at pg/mL level in 
human serum.  The method was validated using the optimized LC-MS/MS 
parameters.   
 
5.2 Experimental 
5.2.1 Reagents 
Dichloromethane and formic acid were obtained from EMD 
Chemical Inc. (Gibbstown, NJ, USA). Methanol and acetonitrile were 
obtained from Pharmco (Brookfield, CT, USA). Dansyl chloride (reagent 
grade) and β-Glucuronidase/sulfatase from Helix pomatia (Type H-2) were 
purchased from Sigma Chemical co. (St. Louis, MO, USA). Sodium 
bicarbonate, glacial acetic acid and L-ascorbic acid were purchased from J. 
T. Baker (Phillipsburg, NJ, USA). Sodium hydroxide and sodium acetate 
were purchased from Fisher Scientific (Fairlawn, NJ, USA). Delipidized 
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double charcoal stripped human serum was purchased from Golden West 
Biologicals (Temecula, CA, USA).  Fifteen estrogens and metabolites (see 
Figure 5.1), including estrone (E1), estradiol (E2), estriol (E3), 16-epiestriol 
(16-epiE3), 17-epiestriol (17-epiE3), 16-ketoestradiol (16-ketoE2), 
16α-hydroxyestrone (16α-OHE1), 2-methoxyestrone (2-MeOE1), 
4-methoxyestrone (4-MeOE1), 2-hydroxyestrone-3-methyl ether (3-MeOE1), 
120 
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2-methoxyestradiol (2-MeOE2), 4-methoxyestradiol (4-MeOE2), 
2-hydroxyestrone (2-OHE1),  4-hydroxyestrone (4-OHE1) and 
2-hydroxyestradiol (2-OHE2), were purchased from Steraloids, Inc. 
(Newport, RI, USA). Deuterium-labeled estrogens and  metabolites, 
including estradiol-2,4,16,16-d4 (d4-E2), estriol-2,4,17-d3 (d3-E3), 
2-hydroxyestradiol-1,4,16,16,17-d5 (d5-2-OHE2) and 
2-methoxyestradiol-1,4,16,16,17-d5 (d5-2-MeOE2), were obtained from 
C/D/N Isotopes, Inc. (Pointe-Claire, Quebec, Canada). The estrogens, 
metabolites and the deuterium-labeled analytical standards were ≥98% pure. 
 
5.2.2 Instruments 
A vortex-mixer (Model: 37600) and a dri-bath (Model: DB-16525) 
from Thermolyne Corporation (Dubuque, IW, USA) were used for 
vortex-mixing and heating of the derivatization reaction. A zymark turbovap 
LV evaporator (Model: ZW700) from Sotax Corp (Horsham, PA, USA) was 
used for evaporating the solvents from the samples. The LC-MS/MS system 
consisted of a Shimadzu SIL HTc auto sampler, two Shimadzu LC-10AD VP 
series pumps, a degasser, a SCL-10 Avp system controller, a CTO-10AS 
column oven (Columnbia, MD, USA), and an Applied Biosystems/Sciex 
(Concord, ON, Canada) model API 5000 triple quadrupole mass 
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spectrometer controlled by Analyst software. A Harvard Apparatus (South 
Nathick, MA, USA) syringe pump with a 500 L syringe from Hamilton Co. 
(Reno, NE, USA) was employed for compound infusion.  A Synergi 
Hydro-RP 2.5 µm 80 Å column, 100 x 2.0 mm, a Kinetex 2.6 µm C18 
column, 100 x 2.1 mm, and a Synergy Hydro-RP 4 µm 100 Å column, 150 x 
2.0 mm, were purchased from Phenomenex (Torrance, CA, USA). An 
Asentis Express 2.7 µm C18 column, 100 x 2.1 mm, was purchased from 
Sigma–Aldrich/Supelco (St. Louis, MO, USA). 
 
5.2.3 Standard preparation 
5.2.3.1 Stock and working standard solutions 
Each stock solution of the estrogens, metabolites or the 
deuterium-labeled analytic standards was prepared at 80-200 g/mL by 
dissolving an accurate weighed standard with methanol containing 0.1% 
(w/v) L-ascorbic acid in a volumetric flask. The working standard solutions 
of estrogens and metabolites at 400-4000 ng/mL and the deuterium-labeled 
standards at 100 ng/mL were prepared by diluting the stock solutions with 
methanol containing 0.1% (w/v) L-ascorbic acid. The stock and working 
standard solutions were stored at –20ºC, and were equilibrated at room 
temperature before analysis. 
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5.2.3.2 Calibration standard and quality control samples 
The calibration standards of the fifteen estrogens and metabolites 
were prepared in a range of 12-10980 pg/mL by sequentially diluting 
working standard solutions with charcoal stripped human serum containing 
0.1% (w/v) L-ascorbic acid to 10 concentration levels. The quality control 
standards were prepared at four levels: limit of quantitation (LOQ, 12-87 
pg/mL), low quality control (LQC, 30-210 pg/mL), medium quality control 
(MQC, 75-801 pg/mL) and high quality control (HQC, 761-8465 pg/mL) of 
the estrogens and metabolites. The deuterium-labeled internal standard (100 
ng/mL), 20 L, was added to each of the calibration standard solutions and 
the quality control solutions. 
 
5.2.3.3 Sample Preparation 
The deuterium-labeled internal standard (100 ng/mL), 20 L, the 
enzymatic hydrolysis buffer containing 2 mg of L-ascorbic acid, 0.5 mL, the 
-glucuronidase/sulfatase solution, 5 L, and 0.15 M sodium acetate buffer 
(pH=4.1), 0.5 mL, were added to 0.5 mL of each serum sample. This sample 
mixture was incubated at 37 ºC for 20 hours. Then the sample mixture was 
extracted with 8 mL of dichloromethane for 10 minutes. The aqueous phase 
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was discarded, while the organic phase was transferred into a test tube, and 
was evaporated at 60 ºC under nitrogen flow to dryness. The dried sample 
was mixed with 150 L of 0.1 M sodium bicarbonate buffer (pH=9.0) and 
150 L of dansyl chloride solution (5 mg/mL in acetonitrile) and vortexed 
for 1 minute. This mixture was transferred into a 400-L glass insert in a 
2-mL HPLC sample vial, and the vial was sealed by an HPLC vial cap.  
After the vial was heated at 60 ºC for 15 minutes, it was cooled down to the 
room temperature, and was analyzed by LC-MS/MS. The same preparation 
procedures of hydrolysis, extraction and derivatization were used for all of 
the standard and the serum samples.  
 
5.2.4 Analytical procedures 
5.2.4.1 Method development 
 The method development was performed using a Phenomenex 
Synergi Hydro-RP 2.5 µm column, a Phenomenex Kenetex 2.6 µm C18 
column and a Supelco Asentis Express 2.7 µm C18 column.  The 
LC-MS/MS parameters listed in Tables 5.1 and 5.2 were evaluated in order 
to optimize sample derivatization procedures, LC separation efficiency and 
MS/MS detection sensitivity, e.g. derivatization temperatures and reaction 
time, column temperature, mobile phases (buffers at difference pHs and 
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different organic phase gradients at different flow rates), injection volume, 
and MS/MS conditions (gas temperature, voltage, collision energy, etc.).  
The MS instrument was tuned with the optimized parameters using the 
dansyl derivatized estrogens and metabolites before method validation.  
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5.2.4.2 Method validation 
After the LC-MS/MS parameters listed in Tables 5.1 and 5. 2 were 
optimized during the method development, the method was validated to 
confirm the specificity, accuracy, precision, linearity, sensitivity, recovery of 
sample hydrolysis and derivatization, and sample stability using a 
Phenomenex Synergi Hydro-RP 2.5 µm column. The four quality control 
standard solutions (LOQ, LQC, MQC and HQC) were injected six times 
each on the first day, and six times on each of the following two days to 
assess accuracy and precision. The ten calibration standard solutions were 
injected for evaluating the linearity of each estrogen or metabolite. To 
evaluate the sample stability, the serum samples were kept on bunch at 
ambient temperature for 4 hours, and were allowed to go through three freeze 
(-80 ºC)/thaw (room temperature) cycles in three consecutive days.  Then 
the serum samples were hydrolyzed, derivatized and analyzed by 
LC-MS/MS. In order to compare our method with a typical published 
method in sample preparation, LC separation efficiency and MS detection 
sensitivity, we evaluated the recovery of sample hydrolysis and extraction, 
and analyzed one set of dansylated estrogens and metabolites at LOQ level 
using both our method and the published method [181].  
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5.3 Results and discussion 
5.3.1 Method development  
 The previous published dansyl chloride derivatization procedures 
were mixing the dried estrogen sample with 50-100 µL of dansyl chloride at 
1 mg/mL in acetone, and heating at 60 ºC for 3 min [43], 5 min [181] or 15 
min [171]. In our experiment, the derivatization reaction was evaluated with 
150 µL of dansyl chloride at different concentrations, i.e. 1, 3 or 5 mg/mL in 
acetonitrile; and with different reaction times at 60 ºC, i.e. 3, 5, 7, 10, 15, 20, 
25 or 30 min. The reason of changing solvent from acetone to acetonitrile 
was that dansyl chloride had a higher solubility in acetonitrile than in 
acetone. The results indicated that the derivatization reaction was complete 
enough when the extracted and dried sample from 0.5 mL of serum reacted 
with 150 L dansyl chloride (5 mg/mL) at 60 ºC for 15 minutes.  A lower 
dansyl chloride concentration or a shorter reaction time led to an incomplete 
derivatization, while a longer reaction time resulted in degradation of the 
derivatized products, e.g. a darker reaction solution and higher baseline 
noises during LC-MS/MS analysis.  
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 As sown in Table 5.2, those mobiles phases, e.g. 25 mM ammonium 
formate at pH 3.0, 25 mM ammonium acetate at pH 4.7, 0.1% formic acid, 
and different ratios of methanol, acetonitrile, isopropanol and 
tetrahydrofuran at different flow rates, e.g. 0.2, 0.3, 0.4 and 0.5 mL/min were 
assessed to obtain the most efficient separation for the fifteen estrogens and 
metabolites.  The final choice of mobile phases were 0.1% formic acid in 
water as Mobile phase A, and 0.1% formic acid in a premixed mixture of 
85% methanol and 15% acetonitrile (v/v) as Mobile phase B at a flow rate of 
0.4 mL/min, because the mobile phases containing ammonium formate, 
ammonium acetate, isopropanol and tetrahydrofuran, and the other flow rates 
reduced the separation efficiency.  The column temperature at 60 °C 
provided a lower column pressure and better separation than at 40-50 °C. 
The injection volume, 20 µL, gave in an appropriate sensitivity for estrogens 
and metabolites, because a lower injection volume, e.g. 15 µL or less, 
reduced the analyte signals, while a higher injection volume, e.g. 40-80 µL, 
elevated baseline noises.  A Phenomenex Synergi Hydro-RP 2.5 µm 
column became the final choice of our method, because it provided a better 
separation for the fifteen dansylated estrogens than a Phenomenex Kenetex 
2.6 µm C18 column and a Supelco Asentis Express 2.7 µm C18 column.  
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 In comparison to the typical published method [181], our method 
derivatized the serum sample with dansyl chloride at a higher concentration 
(5 mg/mL vs. 1 mg/mL) and for a longer time (15 min vs. 3 min), and 
improved the separation of the fifteen estrogens and metabolites by a smaller 
particle size column (2.5 µm vs. 4.0 µm) eluted with mobile phases 
containing water, methanol, acetonitrile and formic acid. The shorter column 
(100 mm vs. 150 mm), higher column temperature (60 °C vs. 40 °C) and 
faster mobile phase flow rate (0.4 ml/mL vs. 0.2 ml/mL) significantly 
reduced the method run time from 100 minutes to 35 minutes, as 
summarized in Table 5.3. The typical overlays of MRM chromatographic 
profiles of dansylated estrogens and metabolites from the published method 
and from our gradient method are shown in Figure 5.2 and Figure 5.3, 
respectively. These figures and the retention times of the fifteen estrogens 
and metabolites listed in Table 5.4 demonstrated that the two pairs of 
E3/16-ketoE2 and 2-MeOE2/4-MeOE1 peaks were overlapped in the 
published method, while they were separated by our gradient method with 
the retention time differences between peaks ≥ 0.2 min.
132 
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  When we eluted the Hydro-RP 2.5 µm column with an isocratic 
mobile phase consisting of 30% water , 70% organic phase  
(methanol/acetonitrile=85/15) and 0.1% formic acid, the separation of the 
fifteen estrogens and metabolites was similar as that from the gradient 
method, as shown in Figure 5.4.  However, the peak heights of three peaks 
between 23 and 26 minutes were much lower than those from the gradient 
method, leading to decreased method sensitivity.  Therefore, the gradient 
method was selected for our method validation.    
       
5.3.2 Method validation 
5.3.2.1 Specificity 
 As shown in Table 5.4 and the typical overlay of selected ion 
chromatograms of fifteen dansylated estrogens and metabolites at HQC level 
in Figure 5.3, most of the estrogens and metabolites were well separated, 
except that 4-MeOE1/E1 and 4-OHE1/2-OHE2 were partially overlapped.  
Since dansylated 4-MeOE1, E1, 4-OHE1 and 2-OHE2 had different molecule 
ions, there were no cross interferences among these compounds in accuracy, 
precision, linearity and sensitivity. The only significant interference from 
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blank serum was observed for E3 at the LQC and LOQ levels. These results 
indicated that the method was specific for these estrogens and metabolites. 
 
 So far, the most efficient LC-MS/MS method was reported by Yang 
et al., which could separate fifteen (out of sixteen) N-methyl nicotinic acid 
ester derivatized estrogens and metabolites in seven minutes using an Agilent 
XDB-C18, 50 x 2.1 mm, 1.8 µ column [170]. However, that method had a 
limit of detection (LOD) within a range of 0.36-2.34 ng/mL, far higher than 
the LOQ range (5.3-71.1 pg/mL) of our method. The separation efficiencies 
of other published methods for varieties of derivatized estrogens and 
metabolites were not so good, although they had comparable sensitivities 
[169,171-173,181].  
 
5.3.2.2 Method sensitivity 
The sensitivity of our method is presented as LOQ with a signal to 
noise ratio of 10 to 1.  In general, the LOQ values listed in Table 5.4 are in 
a range of 5.3-71.1 pg/mL (6.6 pg/mL for E1, 11.7 pg/mL for E2 and 5.3 
pg/mL for E3), and are comparable to those LOQ values acquired using the 
typical published method by Xu et al. (LOQ = 8 pg/mL reported in the 
original article [181]), and to those LOQ values (0.4-10.0 pg/mL) from other 
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published LC-MS/MS and GC-MS/MS methods using varieties of 
derivatization reagents [157,169,171-173].    Nevertheless, the LOQ 
values in Table 5.4 seem having an increasing trend following the retention 
time.  This might be because the longer the retention time, the broader and 
shorter the peaks, leading to lower detection sensitivities.  In addition, the 
differences in ESI+ ionization and fragmentation in MS/MS stage for 
different compounds might also cause the variations in the LOQ values.  On 
the other hand, detection of dansyl derivatives of estrogens and metabolites 
using ESI+ mode might be less selective than detection of pentafluorobenzyl 
estrogen derivatives under APCI- mode [43], because most of the dansylated 
estrogens and metabolites had the same daughter ions of m/z 171+, as shown 
in Table 5.1. This suggested that an optimal sulfonyl chloride derivatisation 
reagent should have more specific fragment ions for the derivatized 
estrogens and metabolites, and the sensitivity should be enhanced more 
dramatically if the fragment ions contain an isotope(s), e.g. a chlorine or 
bromine atom(s).  
 
5.3.2.3 Accuracy 
Accuracy of this method was determined by analyzing duplicate 
sample preparations of the estrogens and metabolites at the four quality 
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control levels, HQC, MQC, LQC and LOQ, and the measure results were 
compared with the theoretical values.  As shown in Tables 5.5 and 5.6, the 
accuracy values at all these levels were within a range of 93.1-112.9% for 
intraday results, and within a range of 91.7-109.8% for interday results, 
except those for E3 at LQC and LOQ levels due to interferences from the 
blank serum.  These results were comparable to those from the methods 
reported before [171,181].  
 
5.3.2.4 Precision 
The precision of the method was assessed by evaluating both method 
precision (intraday precision) and system repeatability (interday precision).  
The method precision for the estrogens and metabolites was presented by the 
relative standard deviation of the response of six sample preparations 
(RSD%, n=6) at the same levels of LOQ, LQC, MQC and HQC on the same 
day.  The relative standard deviations of six sample preparations (RSD%) 
of estrogens and metabolites on the same day (intraday) were in a range of 
1.7-13.2% within the concentration range of 12-8465 pg/mL, as shown in 
Table 5.5. Similarly the relative standard deviations of six sample 
preparations (RSD%) of the estrogens and metabolites in three consecutive 
days (interday) were in a range of 2.3-16.9% within the concentration range 
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of 12-8465 pg/mL, as shown in Table 5.6. These results demonstrated that 
the method had suitable precision and system repeatability within the 
determination ranges.      
  
5.3.2.5 Linearity and recovery of sample derivatization  
   As shown in Table 5.7, the LC/MS/MS system had linear responses to 
the fifteen dansylated estrogens and metabolites in the range of 12-10980 
pg/mL with regression coefficients r2 ≥ 0.9934.  Since a large portion of the 
fifteen estrogens and metabolites exist as glucuronide and sulfate in human 
body fluids, e.g. serum and urine, the conjugated estrogens and metabolites 
need to be hydrolyzed with glucuronidase and sulfatase before dansyl 
derivatization. When we followed glucuronidase/sulfatase hydrolysis 
procedures from the published method [181], and derivatized the 
unconjugated fifteen estrogens and metabolites with dansyl chloride under 
our optimized conditions, the total recovered estrogens and metabolites were 
within a range of 74.4-95.6% at a concentration range of 30-801 pg/mL, as 
shown in Table 5.7.  This range of recovery ratio of sample hydrolysis and 
derivatization was proved to be adequate for sample analysis by the results of 
accuracy, precision, linearity and sensitivity.  In order to demonstrate the 
suitability of the method for real human serum sample analysis, three batches 
 142 
of unknown human serum samples were analyzed.  As shown Table 5.7, the 
levels of the determined estrogens and metabolites by our method were close 
to those from the typical method reported before [181].  
    
5.3.2.6. Sample stability 
The sample stability was evaluated by allowing the serum samples 
spiked with estrogens and metabolites to stay at the room temperature for 
four hours, or to go through three freeze/thaw cycles in three consecutive 
days.  Then, these samples underwent hydrolysis, derivatization and 
LC-MS/MS analysis. The accuracy (82.3-118.1%) and precision 
(2.0-9.0%RSD) results demonstrated that the samples were stable during the 
stability testing, and suitable for sample analysis under the assigned storage 
conditions, as shown in Table 5.8.  
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5.4 Conclusions 
An efficient LC-MS/MS method was successfully developed and 
validated for determination of fifteen estrogens and metabolites in human 
serum. The sample derivatization procedures were optimized, and sample 
stability was assessed. The method was specific, accurate, precise, sensitive 
and linear within the calibration range. It had a comparable sensitivity to 
those from the typical published LC-MS/MS methods, while it had a much 
better LC separation efficiency, i.e. separating all of the fifteen dansylated 
estrogens and metabolites with a significantly reduced elution time.    
 
The information in Chapter 5 has been adapted from a manuscript which is 
in preparation for publication in J. Chromatogr. B. 
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Chapter 6: Facilitating the Hyphenation of CIEF and MALDI-MS for 
Two-Dimensional Separation of Proteins  
  
6.1 Introduction 
Isoelectric focusing (IEF) is one of the most popularly used techniques 
for protein separations. In IEF, proteins are self-focused into narrow zones at 
positions corresponding to their pI values and the widths of these zones are 
inversely proportional to the square root of the focusing electric field 
strength. Theoretically, any protein zone can be compressed into a line-like 
band as long as the electric field strength is sufficiently high. In practice, 
however, the magnitude of the electric field strength is constrained by Joule 
heating. To overcome this problem, IEF is performed in a narrow-bore 
capillary (capillary isoelectric focusing or CIEF for short [182,183] in which 
excess Joule heat can be effectively dissipated through the wall of the 
capillary due to the increase surface-to-volume ratio.  
 
The operation of CIEF consists of two major steps. In the first step, a 
mixture of carrier ampholytes and proteins is introduced into a capillary, and 
a DC voltage is applied to form a pH gradient and focus proteins inside the 
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capillary. In the second step, the focused protein zones are mobilized passing 
through a detector for measurement. The mobilization can be executed 
hydrodynamically [184], electroosmotically [185], or chemically [186]. 
Usually, the separated proteins are detected using a fixed-point UV 
absorbance or fluorescence detector. A whole-column detection approach has 
also been used recently to detect focused proteins without the mobilization 
step [187,188]. While these detectors work well to monitor the separations, 
they are incapable of identifying the separated proteins. Incorporation of 
CIEF with a mass spectrometer (MS) can potentially address this issue. 
 
Coupling of CIEF with electrospray (ESI) MS was accomplished in 
the 1990’s [19,58,189-191], and is capable of providing attomole sensitivity 
due to the concentration effect associated with CIEF [192]. CIEF-ESI-MS 
has been successfully applied for the analysis of a single protein (e.g., 
hemoglobin [58], alcohol dehydrogenase isoenzymes [193] and complex cell 
lysates [194,195]. Matrix-assisted laser desorption/ionization (MALDI) MS, 
introduced in 1988 [196,197], is another MS technique that is widely utilized 
for protein analysis. MALDI-MS is capable of analyzing large intact proteins 
with molecular mass in excess of 100 kDa [198]. However, 
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CIEF-MALDI-MS attracted much less attention than CIEF-ESI-MS, 
presumably due to the challenges of coupling CIEF with MALDI-MS.  
 
In 1995, Foret et al.. [59] demonstrated the feasibility of off-line 
coupling of CIEF with MALDI-MS. In Foret’s apparatus, a fiber-optic UV 
detector was attached to a CIEF capillary to determine the mobilization 
speeds and measure the bandwidths of separated proteins. With these 
parameters, every separated protein band was precisely fractionated. A 
sheath flow unit was incorporated at the exit of the capillary to facilitate the 
fractionation and distribution of these bands to a parallel-glass-tube 
collection interface [190]. An aliquot (2 L) of each collected sample was 
then deposited onto a MALDI target. After the solvent was evaporated, 2 L 
of a matrix solution was added. Evaporation of the matrix solvent resulted in 
the formation of protein-matrix crystals on the sample spot. This sample was 
then analyzed by a MALDI-MS. More recently [199,200], CIEF-separated 
proteins, along with the focusing medium, were fractionated via a sheath 
flow unit and deposited directly onto a MALDI-MS target. Peak resolution 
of this method increased with the decreasing deposition times. Under 
optimized conditions, most of the CIEF resolution was retained [199]. 
However, the additives (ampholytes and surfactants) in the focusing medium 
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reduce the MS signals considerably. In our lab, the similar effect was 
observed: Pharmalyte™ and 3-[(3-Cholamidopropyl)dimethylammonio] 
-1-propanesulfonate (CHAPS) severely suppressed the MS sensitivity. 
Because adequate additives are required to achieve proper CIEF separations, 
minimizing the signal suppression effect of these additives is therefore 
important.  
 
In this work, we report a simple means to mitigate the above adverse 
effect. We first dropped a small volume (~1 L) of water onto a MALDI-MS 
target. We then distributed a fraction of the CIEF-separated sample (~0.1 
L) to the center region and close to the bottom of the droplet. Likely 
because small additive molecules (carrier ampholytes, detergent and other 
salts) diffused faster than proteins, more protein molecules remained in the 
center region of the sample spot after the solvent was evaporated. By 
directing the laser to this region to ablate the sample, we improved the MS 
signal to noise ratio (S/N). We optimized the droplet volume and the 
laser-ablation region to maximize the S/N. We also applied this method for 
analysis of Apolipoprotein A-I (apoA-I, a membrane protein) expressed in E. 
Coli cells. 
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6.2 Materials and methods 
6.2.1 Materials 
Ribonuclease A (13.7 kDa, pI 9.60), horse myoglobin (16.9 kDa, pI 
7.35 and 6.85), β-lactoglobulin B (18.3 kDa, pI 5.30), β-lactoglobulin A 
(18.4 kDa, pI 5.15), soybean trypsin inhibitor (20.1 kDa, pI 4.55), 
3-(trimethoxysilyl)propyl methacrylate, -cyano-4-hydroxycinnamic acid 
and cellulose acetate (CA) (39.7 wt%, average MW 50 kDa) were purchased 
from Sigma (St. Louis, MO). Pharmalyte (36% w/v, pH 3-10) was purchased 
from Amersham Bioscience (Piscataway, NJ). Acrylamide (AA), 
N,N’-methylene-bisacrylamide (Bis), ammonium persulfate (APS), and 
N,N,N’,N’-tetramethylethylenediamine (TEMED) were bought from 
Bio-Rad Laboratories (Hercules, CA). CHAPS was obtained from Acros 
Organics (Morris Plains, NJ). Ammonia acetate was purchased from 
Mallinckrodt Chemicals (Phillipsburg, NJ). Phosphoric acid (85%), sodium 
hydroxide, acetic acid, acetone, trifluoroacetic acid (TFA), methanol, and 
acetonitrile were bought from Fisher Scientific (Pittsburgh, PA). All 
solutions were prepared with ultrapure water purified by a NANOpure 
infinity ultrapure water system (Barnstead, Newton, WA). Fused-silica 
capillaries were purchased from Polymicro Technologies (Phoenix, AZ). 
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6.2.2 Preparation of cross-linked polyacryamide coated capillary  
The coating procedure was similar to that reported previously [201], 
with slight modifications. Briefly, a fused-silica capillary (60 cm long  150 
m i.d.  375 m o.d.) was washed with 1.0 M NaOH for 45 min, rinsed 
with DI water and acetonitrile each for 15 min, and then dried by flowing 
helium at 5 psi for 20 min. A solution of 0.40% (v/v) of 3-(trimethoxysilyl) 
propyl methacrylate and 0.20% (v/v) acetic acid in acetonitrile was flushed 
into the capillary for 1 hour. The capillary was then rinsed with acetonitrile 
for 15 min and dried by flowing helium at 5 psi through the capillary for 20 
min. After 2.0 mL solution containing 4.0% (w/v) of AA and 0.024% Bis 
was purged with helium at 5 psi at room temperature for 1 hour, 1.0 L of 
10% APS and 10 L of TEMED were added to the solution. This solution 
was immediately pressured into the capillary. After 1.5 min, the solution was 
pushed out with pressurized helium at 60 psi, and the helium was allowed to 
continuously blow through the capillary for 1 hour. The capillary coating 
set-up was shown in Figure 6.1. The capillary was ready to use after it was 
rinsed with water for ~10 min.  
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6.2.3 Apolipoprotein A-I sample 
ApoA-I sample was kindly provided by Ms. Shou Lu in Professor 
Zgurskaya’s group in the Department of Chemistry and Biochemistry at 
University of Oklahoma. The sample was prepared and quantitated according 
to a previously published procedure [202].  
 
6.2.4 Construction of cellulose acetate membrane grounding interface  
The construction procedure was similar to that described by Whang 
[203] and Chen and Wang [64], with minor modifications. Briefly, a fracture 
was first produced at ~1.5 cm from one end of a cross-linked polyacryamide 
(CPA)-coated capillary, and a tiny drop of 12% (w/v) CA solution in acetone 
was applied to the fracture to evenly cover it. After the solvent was 
evaporated, a CA membrane was formed around the fracture. A small hole 
was then created at the bottom of a 0.65 mL plastic vial (Fisher Scientific, 
Pittsburgh, PA), and the vial was affixed to the CPA coated capillary with 
CA-covered fracture inside it (see Figure 6.2). Epoxy (Devcon, Riviera 
Beach, FL) was used to secure the vial and the capillary in position and seal 
the hole.  
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6.2.5 Apparatus  
Figure 6.2 presents a schematic diagram of the experimental apparatus. 
The above CPA coated capillary with a CA membrane grounding interface 
was used to perform CIEF separation, and the focusing voltage was provided 
by a Glassman high-voltage power supply (High Bridge, NJ). The anode was 
inserted in the anolyte and the cathode in the catholyte. The exit end of the 
capillary was immersed in the water in the auxiliary reservoir. As the 
separated proteins were mobilized from anode to cathode, they were 
monitored by a Linear-200 UV/visible detector (Linear Instruments Corp., 
Reno, NV) at 280 nm. The absorbance signal was acquired by an NI 
multifunctional card DAQCard-6062e (National Instruments, Austin, TX), 
and processed with an in-house-developed LabView program.  
 
6.2.6 CIEF  
To prepare for CIEF, the separation capillary along with the CA 
membrane grounding interface were rinsed with DI water, and the vial of the 
interface was loaded with a catholyte solution (20 mM of sodium hydroxide). 
After the capillary was filled with a mixture of protein(s) and focusing 
medium (Pharmalyte, CHAPS, and ammonia acetate), its exit end was 
inserted into a small container containing DI water (see Figure 6.2). The 
other end of the capillary was inserted into a container containing an anolyte 
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solution (10 mM of Phosphoric acid). Isoelectric focusing was initiated by 
applying a high voltage (20 kV) from the anolyte solution to the catholyte 
solution, and took ~20 min to complete. For absorbance detection of CIEF 
separated proteins, the focused bands were hydrodynamically mobilized to a 
UV/visible detector by lifting the anolyte solution by 2 cm relative to the 
water in the auxiliary reservoir at the exit end of the capillary while the high 
voltage was maintained during the entire mobilization process.  
 
6.2.7 Protein fractionation/deposition and MALDI-MS identification 
To prepare for protein fractionation/deposition, 1.0 L of water was 
deposited at designated spot on a MALDI-MS target plate in the ambient 
environment a 3-5 seconds before the completion of CIEF focusing. After 
the auxiliary reservoir hosting the exit end of the capillary was removed, the 
MALDI-MS target plate with the water droplet was lifted (in the z-axis via a 
translation stage) so that the capillary tip was inserted into the water droplet 
with the capillary tip virtually touching the target plate. By raising the 
anolyte solution by 2 cm, the solution inside the capillary was delivered to 
the water droplet. During this delivering process, 1.0 L of water was 
deposited at another spot on the target plate. After 30 second delivery, the 
target plate was dropped by 2-3 mm in the z-axis, shifted 4.5 mm in the x- or 
y-axis and lifted 2-3 mm in the z-axis for deposition/delivery to the next spot. 
This operation was repeated until all the focused proteins inside the capillary 
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were delivered to the target plate. During this process, the high voltage was 
applied across the capillary continuously.  
 
After the above fractionation process was complete, the solvent in the 
water droplets were allowed to evaporate. It took ~9 min for each 1.0 L 
water-droplet to get dried under the ambient conditions. Then, 0.5 L 
MALDI matrix [10 mg/mL -cyano-4-hydroxycinnamic acid in 50% (v/v) 
water-acetonitrile with 0.1% (v/v) TFA] was added to each spot and allowed 
to dry again (which took ~5 min). Finally, the target plate was loaded into an 
Applied Biosystems 4800 Proteomics Analyzer for MALDI-MS 
identification. The m/z range of the system was set to 11 kDa-22 kDa or 35 
kDa with a focus m/z of 16 kDa or 23 kDa in linear mode. MALDI-TOF 
spectra were analyzed using Data Explorer software Version 3.0 (Applied 
Biosystems). 
 
6.3 Results and discussion 
6.3.1 Effects of additives on MS signal-to-noise ratio 
To examine the effect of additives on MS signal to noise 
(peak-to-peak noise) ratio, we mixed Pharmalyte or CHAPS (not both) at 
varying concentrations with a protein, and deposit this solution (~0.2 L per 
spot) either directly onto a MALDI-MS target plate or into a 1 L water 
droplet on the target plate. After the solvent was evaporated, we added 0.5 
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L of MALDI-MS matrix (10 mg/mL -cyano-4-hydroxycinnamic acid) to 
each sample spot and allowed the sample to dry again.  
 
As shown in Figure 6.3, in this experiment, the sample contained 
0.05 g/L horse myoglobin and varying concentrations of Pharmalyte or 
CHAPS (not both). 0.2 L of this sample was delivered either directly to a 
MALDI target plate (for Figures 6.3A and 6.3C) or to 1 L of water 
pre-deposited on the target plate (for Figure 6.3B and 6.3D). The sample was 
allowed to dry, and 0.5 L of a matrix solution containing 10 mg/mL of 
-cyano-4-hydroxycinnamic acid and 0.1% TFA in 1:1 acetonitrile-water 
was added to the sample spot. After the matrix solvent was evaporated, the 
target plate was transferred to an Applied Biosystems 4800 Proteomics 
Analyzer. The MS spectra were measured at an m/z range of 11 kDa-22 kDa 
or 35 kDa with a focus m/z of 16 kDa or 23 kDa in a linear mode. Spectra in 
Figures 6.3A and 6.3B were obtained from the protein-Pharmalyte mixtures, 
while spectra in Figures 6.3C and 6.3D were obtained from the 
protein-CHAPS mixtures. 
 
Figure 6.3 exhibits the effect of Pharmalyte and CHAPS 
concentration on the MS signal. Apparently (see Figure 6.3A and 6.3C), 
these additives severely suppress the MS signal. At 3.6% Pharmalyte, no MS 
signal could be detected. Interestingly (see Figure 6.3B and 6.3D), this effect 
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can be alleviated considerably by depositing the protein mixture to a 1 L 
water droplet pre-loaded on the target plate, with a S/N improvement of 2-10 
fold.  
 
In the above tests, we simply added Pharmalyte or CHAPS to the 
protein for MS measurements. To make the test more representative to the 
experimental protocol for CIEF-MALDI-MS, we performed CIEF with 
different concentrations of Pharmalyte and CHAPS, fractionated the 
CIEF-separated proteins and deposited them (along with the focusing 
medium) into 1-L-water droplets pre-loaded on the target plate. The 
remaining steps of the operations were identical to those in Figure 6.3B. 
Similar results were obtained, which confirmed the severe suppression of the 
MS signal by the additives.  
 
We also tried to deposit the CIEF-separated proteins directly to the 
target plate. This experiment failed because we could not deposit the solution 
to the target plate owing to the solvent evaporation when the solution moved 
out of at the capillary tip. 
 
Since a MALDI matrix solution was utilized to facilitate the protein 
ionization, the question arose if it was possible to use this solution to replace 
the water on the target plate. According to the experimental results the matrix 
solution exacerbated the signal suppression effect.
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The detailed mechanism of how the water droplet reduces the 
signal-suppression effect has not been systematically investigated. 
Presumably, the water droplet might have facilitated a “separation” of the 
additives from the proteins. According to the literature [204,205] the 
diffusion coefficient of a molecular is proportionally to the square root [204] 
or the cubic root of its weight [205]. Since the molecular weights of 
Pharmalytes and CHAPS are close to or less than 600 Da while those of the 
proteins used in this experiment are from 14 to 20 kDa, the diffusion 
coefficient of a protein is 2~6-fold smaller than that of an additive. As the 
mixture of additives and proteins was introduced to the middle of the water 
droplet, small additives diffused rapidly outwards while large proteins stayed 
where they were (diffused slowly). As the solvent was evaporated, the 
additives and proteins were somehow “separated”.  
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Figure 6.4 Effect of detection region on MS signal. Reprinted from [68] 
with permission. 
 
6.3.2 Effects of detection region on MS signal 
After a dry sample spot was produced on the target plate, we focused 
the laser in different regions of the sample spot (see the inset in Figure 6.4) 
and measured the MS spectra. The MS spectra were obtained by moving the 
detection region from the left side to the right side of the sample spot (see 
inset). The sample contained 0.05 g/L horse myoglobin, 0.9% Pharmalyte, 
2% CHAPS and 0.5 mM ammonia acetate. The sample was loaded into a 
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cross-linked polyacryamide coated capillary (60 cm long  150 m i.d.  375 
m o.d.) with a CA membrane grounding interface. A high voltage (20 kV) 
was applied across the capillary for 20 minutes to focus the protein. The 
focused protein was hydraudynamically mobilized by raising the anolyte 
reservoir by 2 cm. The sample exiting the capillary was delivered to 1 L of 
water pre-deposited on the MALDI target plate. After 30 seconds (~0.1 L 
sample collection), the sample was delivered to another water droplet. This 
operation was repeated until all the sample was mobilized out of the 
capillary. The sample was dried, and 0.5 L of the matrix solution was added 
to the sample spot. After the matrix solvent was evaporated, the target plate 
was transferred to Applied Biosystems 4800 Proteomics Analyzer for mass 
spectra measurements.  
 
Figure 6.4 presents the results as the laser was moved from one side 
the sample spot to the other. The highest S/N was obtained from the center 
region, which supported our hypothesis that most of the proteins remained in 
this region while the additives diffused to the edge.  
 
6.3.3 Optimization of water droplet size 
In the above test, the MS signal was likely affected by two 
parameters – the degree of the Pharmalyte and CHAPS being separated from 
the protein and the dilution of the protein. For example, if a large water 
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droplet was used, it should facilitate the protein-additive separation (to 
enhance the MS signal), but it should also dilute/spread the proteins (to 
reduce the MS signal). How will the water droplet size affect the MS signal? 
Figure 6.5 presents the MS signal as a function of water droplet size.  
 
Figure 6.5 Optimization of water droplet size. Reprinted from [68] with 
permission. 
 
The volume of the water droplet pre-deposited on the MALDI target 
plate changed from 0.5 L to 2.0 L. The sample contained 0.05 g/L 
horse myoglobin, 0.9% Pharmalyte, 2% CHAPS and 0.5 mM ammonia 
acetate. ~0.1 L of the sample was delivered to the water droplet. All other 
conditions were the same as in Figures 6.3A and 6.3C. The error bars were 
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obtained by repeating the same tests for three times, from CIEF separation to 
MS measurement. 
 
The signal increased with the droplet size as it changed from 0.5 L 
to 1.2 L, and then decreased from 1.2 L to 2.0 L. Overfilling was also 
observed when the droplet size was larger than 1.2 L. In this experiment, 
we selected 1.0 L droplet size throughout this work. 
 
To validate the above mechanism hypothesis, we deliberately mixed 
the droplet solutions after aliquots of a CIEF-separated protein sample were 
delivered to them. The MS signal-suppression data were comparable to those 
in Figure 6.3B. Although these results cannot validate our hypothesis, they 
suggest that the differential diffusion could be one of the mechanisms which 
had contributed to the de-suppression of the MS signal. A systematic 
investigation of the mechanism is in progress in our lab, and the results will 
be reported elsewhere.  
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6.3.4 CIEF separation of standard proteins 
Figure 6.6 presents the traces of CIEF separations of these proteins. 
The CIEF separations were performed in a cross-linked polyacrylamide 
coated capillary (60 cm long  150 m i.d.  375 m o.d.) with a focusing 
medium containing 0.9% Pharmalyte, 2% CHAPS and 0.5 mM ammonia 
acetate. We employed a 60 cm long and 150 m i.d. (versus commonly 50 
m i.d.) capillary to perform the CIEF separation, because we could load 
more proteins inside the capillary to facilitate the following MALDI-MS 
detection. The mobilized proteins were monitored using an absorbance 
detector at 280 nm. Traces A-D were obtained from individual proteins, and 
trace E was obtained from a mixture of all these proteins. The inset shows 
the linear relationship between mobilization time and pI value. The protein 
positions correlate well with their pI values, evidenced by a good linear 
relationship (R2 = 0.975, see the inset) between mobilization time and 
protein pI.  
 
6.3.5 2-D (CIEF-MALDI-MS) separation of standard proteins 
To demonstrate the fractionation of CIEF-separated proteins for 
MALDI-MS detection, we used the same four proteins as a model sample. 
The sample contained 0.05 g/L ribonuclease A (peak a), 0.0065 g/L 
horse myoglobin (peaks b1 and b2), 0.003 g/L β-lactoglobulin B & A 
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(peaks c1 and c2) and 0.05 g/L soybean trypsin inhibitor (peak d). After 
CIEF, the separated proteins were fractionated and deposited onto a MALDI 
target plate and MS spectrum of each fraction was measured, following the 
procedure as described in the experimental section. The CIEF separation 
results with UV absorbance detection (the trace in plane a of Figure 6.7A 
and the trace at the very top of Figure 6.7B) was obtained following the 
procedure as described in Figure 6.6. The MS spectrum of the standard 
protein mixture (the trace in plane b of Figure 6.7A and the trace on the left 
side of Figure 6.7B) was obtained using proteins without additives. All other 
spectra were obtained following the procedure as described in Figure 6.4, 
with detection at the central region.  
 
All spectra were reconstructed into Figure 6.7A, representing a 
2-dimensional (2-D, CIEF and MALDI-MS) separation in a 3-dimension 
format. In addition, we added the CIEF trace (with UV detection) on plane a 
and MALDI-TOF-MS spectrum of the same mixture on plane b in Figure 
6.7A to assist the identification of all peaks from the 2-D separation. Figure 
6.7B is another representation of the same set of data, from which we can see 
the 2-D separation peaks more clearly.  
 
In this experiment, we used a collection time of 30 seconds for each 
fraction. Based on the results shown in Figure 6.7B, 90% of the CIEF 
resolution was retained. Obviously, when the CIEF resolution is high and the 
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proteins have very close pI values, one should reduce the collection time to 
retain the CIEF resolution. In doing so, one should always keep in mind that 
adequate protein(s) are deposited in the sample spot for MALDI-MS 
detection.  
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To test the limit of detection (LOD) of this method, we performed the 
same tests using more dilute standards, and obtained these LODs (S/N=3): 
ribonuclease A – 7.7 pmol, myoglobin horse – 0.82 pmol, andβ
-lactoglobulin A & B – 0.35 pmol. These numbers are several times higher 
than those of MALDI-MS analysis of pure proteins.  
 
6.3.6 2-D (CIEF-MALDI-MS) separation of ApoA-I 
The practical application potential of this 2-D separation approach 
was demonstrated by analysis of apoA-I, a multifunctional exchangeable 
apolipoprotein whose plasma concentration is inversely correlated with the 
incidence of cardiovascular disease [202]. The sample consisted of 0.05 
g/L ribonuclease A (peak a), 0.124 g/L apoA-I (peak b), and 0.025 
g/L β-lactoglobulin B & A (peak c1 and c2). Peaks d and e were from 
small molecule impurities. All other conditions were the same as described 
in Figure 6.7B. ApoA-I consists of 243-amino acids and has a molecular 
weight of 28.0 kDa. Figure 7 shows the 2-D separation of apoA-I mixed with 
ribonuclease A and β-lactoglobulin A & B. From fractions 40-41, we 
observed two mass peaks, one at ~28.0 kDa and the other at ~14.0 kDa. The 
latter was from the double charged apoA-I. Although apoA-I and 
β-lactoglobulin B were not well separated in the CIEF, and the double 
charged apoA-1 and ribonuclease A were not well separated in the 
MALDI-MS, these proteins were well separated in the 2-D separations.  
176 
 
 
 
 
 
F
ig
ur
e 
6.
8 
T
w
o-
di
m
en
si
on
al
 (
C
IE
F
-M
A
L
D
I-
M
S)
 s
ep
ar
at
io
n 
of
 a
po
A
-I
. R
ep
ri
nt
ed
 f
ro
m
 [
68
] 
w
it
h 
pe
rm
is
si
on
. 
 177 
 
6.4 Concluding remarks 
In this chapter, we have combined CIEF and MALDI-TOF-MS for 
2-dimensional separations of proteins. We have reconfirmed that Pharmalyte and 
CHAPS from CIEF severely suppress the MALDI-TOF-MS signal, and 
developed a simple but effective means to alleviate this effect. We have also 
demonstrated the potential of this method for practical protein analysis.  
 
The material in Chapter 6 is adapted from Chang et al. Electrophoresis 31 (2010) 
2614. The copyright permission is obtained from John Wiley & Sons. 
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Chapter 7: Conclusions and future directions 
 
7.1 Conclusions 
       Hyphenated analytical techniques have broad applications in qualitative 
and quantitative analysis of drug substances and drug products in pharmaceutical 
industry. The established HSGC-FID method is able to screen 44 ICH Q3C class 
2 and 3 residual solvents in drug substances. The LC-MS/MS provides us simple, 
sensitive and robust analytical methods to determine the concentrations and 
pharmacokinetic profiles of highly polar aminoglycosides, lipopeptides, and 
glycopeptides in plasma samples. The studies of TCA concentration on plasma 
protein precipitation and sample recovery demonstrate a reliable sample 
preparation procedure for polar compounds. Meanwhile, an efficient LC-MS/MS 
method is successfully developed and validated for determination of fifteen 
estrogens and metabolites in human serum. The sample derivatization procedures 
are optimized, and sample stability is assessed. The method is specific, accurate, 
precise, sensitive and linear within the calibration range and significantly shortens 
the separation time and increases sample throughput in epidemiologic research. 
The hyphenation of CIEF-MALDI-MS could be potentially used in identifying 
low abundance proteins in proteomics research. Applying a simple interface 
between CIEF and MALDI target plate with small droplet water alleviates the 
signal suppression from the MALDI-MS by removing carrier ampholytes and 
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detergent from the sample spots. Overall, the hyphenated analytical techniques 
offer mutli-dimensional separation and detection and can accelerate drug 
discovery and development process in pharmaceutical industry. 
 
7.2 Future directions 
      As increased sample throughput and fast data processing are desired, 
laboratory automation needs to be addressed with hyphenated analytical 
procedures. The future instruments will emphasize simplifying interfaces to 
combine two or more different techniques for drug discovery. The hyphenated 
techniques combine new technologies, enabling to analyze more difficult samples 
and offer us faster and richer information for drug discovery and development 
[1,206]. 
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